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Introduction
Development of the prevention and control 
of communicable diseases
The Finnish Parliament has given its approval to the 
amended Communicable Diseases Act (www.finlex.fi 
1227/2016) and Decree. The Act entered into force on 1 
March 2017. Compared to its predecessor, the amend-
ed Act, which underwent eventful communication and 
consultation rounds, brings numerous improvements, 
including more specific details on the monitoring, pre-
vention and control of infections related to treatment 
as well as antimicrobial resistance. Statutes concerning 
vaccinations to health care personnel, infection mon-
itoring systems as well as opportunities for obtaining 
information in connection with outbreak investigations 
have been expanded in the new Act. Other amendments 
concerning public authority include sections on health 
examinations and decision-making on absences, the 
new sickness allowance on account of an infectious 
disease as well as licences for microbiological labora-
tories and the import of microorganisms.
The legislative reform could not yet take into account 
the new structures introduced by the health and social 
services reform. However, as the responsibility on the 
prevention and control of communicable diseases and 
infections is likely to be transferred from municipalities 
to counties, there will soon be a need to update the Act. 
In fact, the Ministry of Social Affairs and Health has 
appointed a group operating under the Advisory Board 
on Communicable Disease for this purpose.
The group’s task is to prepare necessary amendment 
proposals. In this context, it is important to ensure not 
only that all necessary activities are transferred, but 
also that sufficient resources and responsibilities are 
allocated to them in the health and social service organ-
isations of the counties. It is also important to maintain 
a relationship with environmental health care to ensure 
that there are no gaps in the prevention and control of 
food and water related epidemics.
A significant reform took place at the departmental 
level in the National Institute for Health and Welfare 
as the operations of infectious disease monitoring and 
control, microbiological specialist laboratories, vacci-
nations and environmental health were united into one 
department. The Department of Health Security began 
its operations on 1 January 2017 and aims to develop 
its operations into an entity providing good service to 
its customers as part of the National Institute for Health 
and Welfare.
International situation
After a few years (Ebola 2014–15, Mers 2015, Zika 
2015), the international situation for cross-border in-
fection threats had become slightly calmer. Meanwhile, 
there was a lot of development work related to the ca-
pability to prevent outbreaks and ensure that they do 
not evolve into extensive regional problems or even a 
global pandemic. Under the guidance of the Ministry 
of Social Affairs and Health, Finland was actively in-
volved in promoting cross-administrative cooperation 
for the implementation of the obligations set in the In-
ternational Health Regulations (IHR 2005) in support 
of the World Health Organisation (WHO). Under the 
guidance of WHO, an external evaluation of the func-
tions required by the IHR was carried out  in over 30 
countries in 2016. Specialists from the National Insti-
tute for Health and Welfare, the Radiation and Nuclear 
Safety Authority, the food safety sector and the defence 
sector also participated in this work. 
On the status of infectious diseases in  
Finland
In the influenza season of spring 2016, the epidemic 
dominant viruses were first A(H1N1)pdm09 subtype 
viruses and, later in the spring, influenza B viruses. The 
epidemic season 2016–2017 started earlier than expect-
ed and was extremely severe, and this time influenza 
A(H3N2) subtype viruses emerged as the epidemic 
dominant viruses. This influenza season was the ear-
liest since the 2009 pandemic. The number of cases in 
the RSV epidemic of season 2016 was exceptionally 
high.
There were outbreaks of intestinal infection caused 
by both Salmonella Enteritidis as well as EHEC and 
EPEC bacteria, most likely caused by the consumption 
of sprouts (Salmonella) and food containing rocket sal-
ad. A new type of norovirus was detected, and this was 
connected to five separate outbreaks around Finland as 
well as one extensive epidemic on a cruise ship from 
May to June 2016. An increase in campylobacter infec-
tions and listeriosis cases in recent years caused some 
concern. No reason is known for this, but the incidence 
of campylobacter infections has also increased in Swe-
den in recent years.
There is also a slight increase in sexually transmitted 
diseases, and a record number of chlamydia and syph-
ilis cases were reported in 2016. The majority of the 
cases of people of Finnish origin had been contracted 
in Finland. 
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In 2016, a national working group prepared a cross-ad-
ministrative strategy on the prevention of antimicrobial 
resistance, which was competed in 2017 and published 
in May. The measures recommended by the strategy 
aim to reverse the upward trend in the resistance. This 
is a necessary step as the number of MRSA infections 
was significantly higher than in the previous year and 
the number of blood cultures also grew. By contrast, the 
situation of cases caused by Carbapenemase-Producing 
Enterobacteriaceae (CPE) continues to be moderately 
good although their number has nonetheless increased. 
In recent years, three clusters of infections caused by 
KPC-3 positive K. pneumoniae (ST512) in care insti-
tutions have been found in Finland. The number of tu-
berculosis drug-resistant Mycobacterium tuberculosis 
strains has also increased slightly in recent years. By 
contrast, the number of tuberculosis cases has not risen, 
as there were fewer cases than in 2015. 
A similar number of severe pneumococcal infections 
was diagnosed as in the year before. The incidence of 
pneumococcal infection increased slightly in children 
under 5 due to the more frequent occurrence of sero-
types not included in the vaccine. However, it is worth 
noticing that since the vaccination programme was 
introduced, severe pneumococcal infections caused 
by PCV10 vaccine serotypes have been almost total-
ly eliminated in young children, and they continued to 
decline in 2016.
Almost 16,000 bacterial findings were detected in cul-
tured blood samples from adults. It is worrying that 
these findings have constantly increased, particularly 
in patients aged 65 or over. Escherichia coli was the 
most common finding in both the working age popu-
lation and in patients aged 65 and over. Other common 
findings included Staphylococcus aureus, a significant 
percentage of which is known to be treatment-related 
infections. As the population is ageing, there would be 
good reason to pay increasing attention to the systemat-
ic prevention and control of these infections both at the 
local and regional level.
An increase was observed in zoonotic diseases that 
follow significant year-to-year variation. More cases 
of Puumala virus were reported than in 2015. The vole 
populations carrying the virus increased especially in 
Southern and Eastern Finland, which was reflected as 
a higher number of cases. More cases of Pogosta dis-
ease were reported than in the year before. A significant 
increase in tuleramia cases was recorded compared to 
recent years; the number of these cases exceeded the 
total number reported in the last six years.
A significant number of cases of exposure to rabies 
can be observed in the infections related to tourism (60 
people, mostly in Thailand and Indonesia, exposure 
through a dog or monkey bite). Nearly all cases of ma-
laria originated in Africa, over half of them were con-
nected to visiting relatives in regions with high malaria 
incidence. Six infections caused by the zika virus were 
diagnosed in Finnish tourists.
Helsinki, 7th August, 2017
Mika Salminen 
Director 
Department of Health Security
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Respiratory infections
• In the influenza season 2015–2016, the dominant viruses were first A(H1N1)pdm09 subtype 
viruses and, later in the spring, influenza B viruses.
• The epidemic season 2016–2017 started earlier than expected and was extremely severe, 
and this time influenza A(H3N2) subtype viruses emerged as the epidemic dominant viruses. 
This influenza season was the earliest since the 2009 pandemic.
• The number of rhinovirus infections peaked in August–December, and almost one half of 
them were found in children aged under 4.
• As expected, the minor winter epidemic of 2015 was followed by a more significant RSV 
epidemic with an exceptional number of cases compared to earlier epidemics of a similar 
nature.
• More enterovirus infections were diagnosed in the autumn than in previous years, including 
type D68. Enterovirus epidemics also occurred in other European countries.
• The number of whooping cough cases was considerably higher than in the year before. 
While the highest number was found in young infants, the incidence was particularly high in 
young people aged 10 to 15.
• Of legionellosis patients, it was confirmed that four had contracted the infection at home or 
in its surroundings, and for one patient, the source of infection was the water supply system 
of a hospital.
ADENOVIRUS
In 2016, 915 confirmed adenovirus infections were record-
ed (2015: 1,134). The largest number of cases was reported 
in the under 5 age group (more than 500), but a moderate 
number was also diagnosed in the 5 to 9 and 15 to 19 age 
groups. In January–April and November–December 
2016, slightly more adenovirus infections were reported 
than in the other months (83–124 cases per month). At 
other times of the year, the monthly numbers of ade-
novirus infections varied between 36 and 66 cases per 
month. 
More than 60 types of adenoviruses are known. Some 
cause respiratory infections, while others cause gas-
trointestinal, eye or other infections. Adenoviruses are 
common pathogens in infants and young children, but 
they also infect adults. 
Laboratories have various test methods for detecting 
adenoviruses in clinical samples. Antigen detection, vi-
rus cultures and PCR are highly sensitive and reliable 
methods used in specialised virus laboratories.
INFLUENZA
The peak weeks of two different influenza epidemics 
were recorded in 2016 that belonged to epidemic sea-
sons 2015–2016 and 2016–2017. Two separate epidem-
ic waves were observed in the first six months of 2016, 
or during influenza season 2015–2016. The dominant 
viruses were A(H1N1)pdm09 subtype viruses in the 
first wave and influenza B viruses later in the spring. 
In late 2016, the epidemic season 2016–2017 started 
earlier than expected and was extremely severe, and 
this time influenza A(H3N2) subtype viruses emerged 
as the dominant viruses. 
Influenza A
In 2016, 20,889 findings of influenza A were reported 
to the National Infectious Diseases Register, which is 
almost three times the previous year’s figure (2015: 
7,723). In the first six months of 2016, 10,281 influenza 
A infections were reported to the National Infectious 
Diseases Register, while this figure for October–De-
cember was 10,562. In May–September, only sporadic 
cases of influenza A infections were diagnosed. 
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Season 2015–2016
The first influenza A infections of the 2015–2016 sea-
son were reported to the National Infectious Diseases 
Register  as early as in October‒November 2015. The 
number of cases increased after mid-November 2015. 
Almost 5,000 diagnoses of influenza A were report-
ed in both January and February.  Unlike in previous 
seasons, more than 1,000–2,000 cases of influenza A 
infections were reported each week. National surveil-
lance of influenza virus infections by the National In-
stitute for Health and Welfare led to the detection of 
152 influenza A infections in the 2015–2016 season, 
of which 92% were diagnosed as having been caused 
by the influenza A(H1N1)pdm09 virus. All A(H1N1)
pdm09 viruses subjected to a closer analysis were 6B.1 
viruses of a new genetic type that were antigenically 
almost identical to the  A/California/07/2009 vaccine 
virus of the season. During the epidemic season, only 
sporadic cases of influenza A(H3N2) infections were 
diagnosed. Genetically analysed A(H3N2) viruses 
belonged to two different groups (3C.2a and 3C.3a), 
which had a good antigenic correspondence to the  A/
Switzerland/9715293/2013 virus included in the vac-
cine.
The National Infectious Diseases Register and the na-
tional influenza surveillance of the National Institute 
for Health and Welfare indicate that the peak period of 
influenza A in 2015–2016 was seen in weeks 2 to 7. 
The numbers of reported influenza A cases remained 
at a moderately high level for several weeks. The case 
numbers only started showing a decline towards the 
end of April and beginning of May, after which only 
individual influenza A infections were diagnosed.  In 
October, the numbers of influenza A cases again started 
to increase, indicating that the season 2016–2017 start-
ed exceptionally early.
Season 2016-2017
2016–2017 was the earliest influenza season since the 
2009 pandemic. After mid-November 2016, there was 
a strong increase in the numbers of influenza A infec-
tions.  In December 2016 and January 2017, 9,418 and 
5,309 influenza A infections respectively were reported 
to the National Infectious Diseases Register. In weeks 
49/2016–2/2017, the number of reported cases exceed-
ed 1,000–3,000 a week. The epidemic virus was of the 
subtype A(H3N2). Between November 2016 and Feb-
ruary 2017, no influenza A(H1N1)pdm09 viruses were 
found. 
In February 2016, WHO recommended that the influ-
enza A(H3N2) virus component be changed to A/Hong 
Kong/4801/2014 for the epidemic season 2016–2017, 
as it would be antigenically a better match with the 
A(H3N2) viruses circulating as epidemics.  
At the beginning of the season, the virus contained in 
the vaccine had a relatively good correspondence to 
the epidemic A(H3N2) viruses, but as the season pro-
gressed, the range of viruses broadened. The viruses 
that circulated as epidemics represented two different 
genetic groups (3C.2a and 3C.2a1). Mutations occurred 
in the viruses of both groups that may have undermined 
the protection given by the vaccine.  In the season 
2016–2017, it was for the first time possible to monitor 
the effectiveness of the vaccine in almost real time by 
combining the data in the National Infectious Diseases 
Register and the National Vaccination Register.
Influenza A infections occurred in all age groups in 
2016. In the period between January and April, 1.5 to 2 
times more influenza A infections were reported in the 
age groups 0 to 4 and 25 to 59 compared to the findings 
reported in October–December. On the other hand, a 
high number of influenza A infections occurred in Oc-
tober-December especially in the over 75 age group 
(January–April: 757 compared to October–December: 
3,023), but also in the age group 65 to 74.  Reasons for 
the different morbidity of the age groups may include 
the fact that the dominant group at the beginning of the 
year was A(H1N1)pdm09 viruses, whereas towards the 
end of the year, A(H3N2) viruses predominated. Based 
on information gathered in previous seasons, it is 
known that during influenza A(H1N1)pdm09 virus sea-
sons, particularly serious infections occur in young and 
otherwise healthy adults in working age, unlike during 
A(H3N2) seasons. In influenza A(H3N2) seasons, seri-
ous infections occur in older persons more often than in 
the other age groups, which may be reflected as higher 
numbers of diagnosed cases in the older age groups.  
While the national vaccination programme has offered 
a free vaccine against seasonal influenza to children in 
medical risk groups since 1980, and to healthy children 
aged 6 to 35 months since 2007, the coverage of the 
influenza vaccines remains low. At best, the coverage 
for children aged 6 to 35 months was approximately 
40% before the pandemic. After the pandemic, the vac-
cination coverages have been monitored based on the 
administered doses reported to the national vaccina-
tion register, and these figures may have some infor-
mation system related shortcomings. The register data 
indicates that the vaccination coverage of young chil-
dren was some 13% at its lowest but has increased in 
small steps since. The vaccination coverage was 24% 
in 2015–2016 as compared to 17% in 2014–2015, and 
in season 2016–2017, it has continued to increase to 
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32%. In 2016, the highest number of influenza A cases 
in children and young people were reported for the age 
group 0 to 4, especially in 2015–2016 (January–April 
2016: 1,346 (in 2016: 2,100). 
In those aged 65 or over, the vaccination coverage was 
42% in 2015–2016, increasing to 47% in 2016–2017. 
Influenza B
As in the year before, a high number of influenza B 
infections were reported to the National Infectious 
Diseases Register in 2016 (2016: 4,729 (in 2015: 
5,462). The influenza season 2015–2016 was the sec-
ond consecutive season in which an obvious influen-
za B epidemic was recorded.  Influenza B infections 
started multiplying in early January, and subsequently, 
a high number was diagnosed between February and 
May, with sporadic cases as late as in early June. From 
March on, the weekly cases of influenza B exceeded 
the number of influenza A cases. Influenza B infections 
peaked in weeks 8 to 16. Between mid-November 2016 
and February 2017, a small number of influenza B in-
fections occurred steadily throughout the period. Influ-
enza B infections occurred in all age groups in 2016.
Of the two influenza B virus lineages that have circu-
lated the world in recent seasons, the Yamagata lineage 
has occurred more frequently than the Victoria lineage. 
For the 2015–2016 season, WHO had recommended 
that the Yamagata lineage virus be again included as the 
B virus component of the trivalent vaccine.  However, 
the influenza B viruses that circulated in winter 2016 
represented the Victoria lineage and differed antigeni-
cally from the vaccine virus (B/Phuket/3073/2017).
Due to the increased occurrence of the Victoria lineage 
viruses, in February 2016 WHO recommended that the 
Victoria lineage virus  B/Brisbane/60/2008 be included 
in the trivalent vaccine for 2016–2017. The B viruses 
that circulated in late 2016 almost exclusively repre-
sented the Yamagata lineage.  
Vaccine for the epidemic season 2017−2018
At the end of February 2017, WHO issued a new vac-
cine recommendation for the 201–2018 epidemic sea-
son in the Northern hemisphere. This recommenda-
tion was based on the data on the epidemic situation 
collected by early February and an assessment of the 
type of influenza viruses that were likely to circulate 
in the forthcoming epidemic season.  The new WHO 
recommendation only concerned replacing the influen-
za A(H1N1)pdm09 component (A/California/07/2009) 
by the A/Michigan/45/2015 virus. The recommenda-
tion proposed that the influenza A(H3N2) virus com-
ponent, or the A/Hong Kong/4801/2014 virus, should 
not be replaced. The use of the Victoria lineage B/
Brisbane/60/2008 virus as the influenza B component 
was further recommended in trivalent vaccines. In ad-
dition to these, B/Phuket/3073/2013, another influenza 
B virus of the Yamagata lineage, was recommended for 
quadrivalent vaccines. 
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Figure 1. Cases of influenza A by month and epidemic virus serotypes, 2007–2016 (no. of cases).
Figure 2. Cases of influenza B by month and epidemic virus serotypes, 2007–2016 (no. of cases).
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PARAINFLUENZA
Parainfluenza viruses are grouped under one head-
ing in the National Infectious Diseases Regis-
ter, even though laboratories usually differen-
tiate between parainfluenza viruses 1, 2, 3 and 
4. In 2016, 604 parainfluenza infections were con-
firmed (2015: 508), most of these in the 0 to 4 age 
group (266 cases).  A moderate number was also re-
ported in the 5 to 9 age group and those aged 65 and 
over. The case numbers started increasing in Novem-
ber–December 2015 and remained at a relatively high 
level during the first six months of 2016. The monthly 
case numbers (64–95 cases/month) peaked in January–
June. 
Parainfluenza virus infections are found in all age 
groups. The first parainfluenza infections in children 
can lead to a severe condition that may require hos-
pitalisation. In an older child or adult, the symptoms 
of a parainfluenza infection are typically much mild-
er. They often present as an ordinary upper respiratory 
tract infection and do not necessarily require labora-
tory diagnostics. In special groups, however, such as 
immune deficiency patients, parainfluenza viruses may 
cause severe symptoms. 
RHINOVIRUS
In 2016, 1,145 confirmed rhinovirus infections were 
recorded (2015: 1,088). The numbers were highest 
in August–December (95 to 195 per month), peaking 
in September. At other times, rhinovirus infections 
occurred at a steady rate every month (48 to 84 per 
month). More than 50% of these infections were diag-
nosed in children under the age of 4.
Over 150 types of rhinovirus are known. They are the 
most common cause of mild respiratory infections. 
While rhinovirus infections are the most common in 
young children, they are present in all age groups. 
Since August 2013, rhinoviruses have been included 
in the surveillance of respiratory virus infections con-
ducted by the Infectious Disease Control unit of the 
National Institute for Health and Welfare, which may 
partly contribute to the increase in the number of cases 
from 2013 to 2016. Laboratories use a PCR test to de-
tect rhinoviruses in clinical samples. This test is highly 
sensitive and reliable. Specialised virus laboratories are 
also able to culture rhinoviruses.
RSV
In 2016, 4,946 cases of RSV confirmed by laboratory 
tests were reported to the National Infectious Disease 
Register (2015: 2,436). As part of long-term surveil-
lance, a major RSV epidemic is observed in Finland 
every other winter, often starting in November–Decem-
ber. In addition, minor epidemics occur between the 
major ones. As expected, the major winter epidemic of 
2015 was followed by a minor epidemic that began in 
November–December 2015 and continued until May. 
During the winter epidemic of 2016, an exceptionally 
high number of cases was recorded compared to previ-
ous major epidemics. During the epidemic, the num-
ber of RSV cases was highest in January to February 
(1,559 and 1,977 per month respectively), peaking at 
over 500 cases per week. The peak of the RSV epi-
demic coincided with the peak numbers of influenza 
A cases in January and February. Individual cases of 
RSV infection were diagnosed during the summer. In 
December, the number of RSV cases again began to 
increase, indicating the start of another RSV epidemic.
The majority of RSV cases (approximately 60%) were 
found in children aged 0 to 4. Slightly more cases of 
RSV, or nearly 20%, were reported in patients aged 
over 75 than in other age groups. Although RSV in-
fections are present in all age groups, cases requiring 
hospitalisation and laboratory diagnostics mainly in-
volve infants and young children, and to some extent 
also older people.
Reliable quick tests for RSV diagnostics have been 
developed for use at health centres, outpatient clinics 
and hospitals. In a hospital environment, RSV is easily 
transmitted between patients. Quick tests make it eas-
ier to identify RSV infections and therefore to prevent 
further transmission. Specialised virus laboratories in-
creasingly use genetic replication methods for diagnos-
ing RSV.
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Figure 3. Cases of RSV by month, 2007–2016 (no. of cases).
ENTEROVIRUS
In 2016, 336 cases of enterovirus infection were re-
ported to the National Infectious Diseases Register, 
considerably more than in 2015 (119) or 2014 (298). 
Most cases were found in the autumn, which is typical 
of enteroviruses, and 83% of the cases were diagnosed 
in August–December. The epidemic peaked in Septem-
ber, with one third of the year’s cases being reported in 
that month (112, 33%). The majority of those infected 
were children: 145 (43%) were aged under 5, and 85 
(25%) were aged 5 to 14. Enterovirus infections were 
diagnosed in all of the 20 hospital districts. The largest 
numbers of cases were found in the hospital districts 
of North Ostrobothnia (85), Southwest Finland (56), 
North Savo (33), North Karelia (29) and Helsinki and 
Uusimaa (25). In other hospital districts, the number 
of enterovirus infections diagnosed remained below 20. 
An increased number of infections caused by entero-
virus D68 were diagnosed in the autumn in many hos-
pital districts. The highest number, mostly respiratory 
infections that required hospitalisation in children, was 
found in Southwest Finland. Around ten enterovirus 
D68 cases were confirmed in the Helsinki and Uusimaa 
Hospital District. Most of these were respiratory infec-
tions in children. During the autumn, young patients al-
so displayed many symptoms typical of the hand, foot 
and mouth disease. Sporadic infections with severe 
symptoms caused by enteroviruses coxsackie A6 and 
coxsackie B5 were also diagnosed in children.
Enteroviruses also caused epidemics in other parts of 
Europe in 2016. In France, a higher than usual num-
ber of serious enterovirus infections in children was 
recorded in May to October. Serious neurological 
symptoms were caused by enterovirus types A71 and 
D68. In Sweden, an increase in infections caused by 
enterovirus D68 was reported. The majority of those 
who were infected were young children, and severe 
symptoms were found in 13% of them. The Swedish 
epidemic peaked in August–September.
WHOOPING COUGH
In 2016, 432 cases of whooping cough were re-
ported to the National Infectious Diseases Regis-
ter (7.9/100,000), which is a significant increase on 
2015 (165). As before, the cases were most common 
in the 0 to 14 age group, with a particularly high in-
cidence in the age group 10 to 14 (28.5/100,000). 
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Thirty-two cases were diagnosed in patients under 12 
months of age, and 14 of them were under 3 months of 
age, thus too young to have been vaccinated. The diag-
nosis of patients aged under 12 months was principally 
based on a PCR test (21/32, 65%). For most patients 
of other ages, the diagnosis was made on the basis of 
antibody testing. 
Of the children 3 to 23 months of age who contracted 
whooping cough and whose vaccination data was avail-
able (26), two had not been vaccinated as indicated by 
their age, two had contracted the infection just before 
they were due the first vaccine, 15 had received one to 
two doses of vaccine containing acellular component 
of pertussis, and in seven, the vaccine failed to protect 
them from the disease. A total of 14 children contracted 
the infection when aged under 3 months. In 2016, three 
of the 26 Bordetella pertussis strains isolated did not 
produce pertactin.
As previously, the incidence of whooping cough varied 
considerably by hospital district (0–15.4/100,000). The 
incidence was highest in the hospital districts of North 
Karelia (15.4) and Helsinki and Uusimaa (12.8). No 
cases were diagnosed in Åland. 
Choosing an optimum vaccination strategy for 
whooping cough is challenging, as the acellu-
lar vaccines widely used in Western countries are 
incomplete in terms of their efficiency and duration. 
A booster for six-year-olds was added to the national 
vaccination programme in Finland in 2003. In 2005, 
the whole-cell vaccine was replaced with an acellular 
combination vaccine containing the Bordetella pertus-
sis antigen for children in the age groups covered by 
child care clinics. Until 2007, adolescent vaccinations 
were given between the ages of 11 and 13. Since 2009, 
the recommendation has been to vaccinate adolescents 
at the age of 14 to 15, i.e. from the 8th grade of com-
prehensive school up. Due to this transition, very few 
of these vaccinations were administered between 2009 
and 2011. This created a temporarily less well protected 
cohort in adolescent age groups. Illness in infancy in-
dicates insufficient herd immunity. A whooping cough 
vaccine for conscripts beginning their military service 
was added to the Finnish Defence Forces’ vaccination 
programme in summer 2012. Consequently, the inci-
dence of whooping cough has decreased considerable 
among those in the age for participating in military ser-
vice. 
So far, Finland has been spared an extensive whoop-
ing cough epidemic that generated more than 40,000 
cases in the United States and almost 10,000 cases in 
the UK during 2012. In 2012, the year the epidemic 
occurred, it was discovered on the basis of an extensive 
strain collection in the United States that 60% of B. 
pertussis strains did not produce pertactin. Both coun-
tries initiated a whooping cough vaccination campaign 
for pregnant women, resulting in a significant reduc-
tion in the number of whooping cough cases in young 
infants. With respect to Finland’s neighbouring coun-
tries, in Sweden the number of whooping cough cases 
increased almost threefold in 2014 and remained high 
in 2015 and 2016 (>600 cases). 
The National Institute for Health and Welfare will 
publish a working paper in spring 2017 containing an 
expert assessment of the epidemiological situation of 
whooping cough in Finland and other Western coun-
tries, proposals for measures, and different vaccination 
strategies to be followed if the incidence of whooping 
cough were to increase substantially in Finland.  
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Figure 4. Cases of whooping cough in children’s and young adults’ age groups, 2007–2016 (no. of cases).
CHLAMYDIA PNEUMONIAE
In 2016, 261 cases of Chlamydia pneumoniae were 
reported based on laboratory verification, mainly 
antibody testing. This figure has remained relatively 
stable over the last five years. The highest incidence 
was reported in the hospital districts of East Savo, Cen-
tral Ostrobothnia and Vaasa, while the number of cas-
es was the highest in the Helsinki and Uusimaa Hos-
pital District (74). The number of reported infections 
was highest in the age groups 5 to 24 (46% of cases) 
and 35 to 59 (40%).
LEGIONELLA
In 2016, 26 cases of legionellosis were reported to the 
National Infectious Diseases Register, of which 9 were 
based on the detection of the antigen in urine, 7 on a 
sputum test, 1 on a PCR test of a needle biopsy and 11 
on serological methods. Further investigation revealed 
that the clinical presentation was consistent with le-
gionellosis in 15 patients, whose chest X-rays revealed 
changes indicative of pneumonia. The average 
age of patients was 60 (variation 17 to 87) and 10 
(67%) of them were male. Nine (60%) individuals had 
contracted the infection while travelling abroad, and 
six (40%) in Finland. Two of the cases proved fatal.
The sources of six cases of infection were ex-
amined more closely through environmen-
tal samples. Legionella bacteria were detected 
in domestic (4/7) and hospital (1/3) water supply sys-
tems. As the source of infection in four patients was 
confirmed the home or its close surroundings (home, 
free-time residence, lawn compost consisting of sew-
age slurry and peat), and in one patient, the water 
supply system of a hospital. In three cases, the source 
of infection was confirmed by genetic analysis of the 
patient and environmental strains (Legionella pneu-
mophila bacteria serotype 1, L. pneumophila bacteria 
serotype 5, L. anisa). In two cases there was strong epi-
demiological evidence (L. longbeachae, L. pneumophi-
la bacteria serotype 1). The homes of two patients who 
had been travelling abroad were investigated, but no 
source of infection was found. This was the first time 
that whole genome sequencing (WGS) was used for the 
genetic comparison of strains.
According to the European guideline for legionella, 
the threshold for measures requiring the cleaning of 
household water supply is more than 1,000 cfu/l of le-
gionella. According to the National Building Code of 
Finland, section D1, the hot water temperature must 
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be 55 to 65°C, and the recommended maximum tem-
perature of cold household water is ≤ 20°C. The water 
temperatures on the premises where the water system 
was found to be the cause of the infection did not com-
ply with these recommendations. Corrective action was 
taken on all of these premises. Especially on larger hos-
pital and hotel premises, water turnover rates may also 
vary, which makes the target water temperature more 
difficult to maintain. Particular care should be taken 
when using vaporisers and air humidifiers, and sterile 
water should be used in their maintenance operations 
as far as possible. Compost and lake water are also po-
tential sources of infection. When spreading compost, 
attention should be paid to working methods, and pro-
tection from the dust emitted by the compost may be 
needed.
Accommodation data relating to all of the patients 
who fell ill abroad was reported to the ELDSNET da-
tabase (European Legionnaires’ Disease Surveillance 
Network), which collects data on travel-related cas-
es of legionellosis. European surveillance indicates 
that the majority (60 to 70%) of cases are of commu-
nity origin, some 20% are associated with travel, and 
fewer than 10% originate in hospitals. 
In Finland, cases of legionellosis are traditionally linked 
with travel, even if its role in Finnish cases has also had 
great variations (20 to 100%), and Legionella is therefore 
often overlooked as a potential pathogen in pneumonia 
cases of domestic origin.  Fast and sensitive molecular 
methods are available for the diagnostics of Legionel-
la, as well as newer urine antigen tests that also detect 
other types than L. pneumophila serotype 1. In cases 
of exposure at home, in hospital and in the workplace, 
awareness of Legionella as a potential cause of the in-
fection is likely to play a critical part. Correct diagnosis 
is crucial for the targeting of treatment and any pre-
vention measures. Culturing to establish the Legionella 
strain in question continues to be important for estab-
lishing the source of infection. 
MYCOPLASMA PNEUMONIAE
In 2016, the total number of Mycoplasma pneumoniae 
cases confirmed in laboratory tests was 2,742. During 
previous epidemics, more than 4,600 cases were report-
ed in 2012, and more than 7,800 in 2011. In late 2015 
and again in early 2016, numerous M. pneumoniae 
cases were diagnosed in Denmark, confirming a dou-
ble-peak epidemic. The situation in Finland has been 
similar to other European countries on many occasions. 
This time, however, no obvious epidemic was observed 
during the corresponding period, even if an increase 
in the number of cases can be seen in the statistics to-
wards the end of both 2015 and 2016. It may be that 
following the high numbers of cases during the previ-
ous major epidemic (2011‒2012), ‘minor’ epidemics 
have gone unobserved.   
The highest number of M. pneumoniae cases are di-
agnosed in the 5 to 19 age group (56 % of cases). As 
in previous years, the majority of cases (almost 900) 
were recorded in the Helsinki and Uusimaa Hospital 
District, in which almost twice as many cases were re-
ported compared to the previous year. The incidence 
was the highest in the Hospital Districts of East Savo, 
Vaasa and North Savo (>70/100,000 in all districts). 
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Figure 5. Cases of Mycoplasma pneumoniae and Chlamydia pneumoniae by month, 2007–2016  
(no. of cases).
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Gastrointestinal infections
• In the March to May period, 22 people in Pirkanmaa contracted an infection caused by 
Salmonella Enteritidis bacteria. The most probably source of the infections was bean 
sprouts of a foreign origin, the seed batches of which were recalled in the Finnish market. 
• As in previous years, the highest number of norovirus infections was recorded in January 
to May. In late winter, a virus strain of a new type was found in five epidemics occurring in 
different parts of Finland.
• A new norovirus type caused a wide-spread gastroenteritis epidemic on a cruise ship in 
May‒June 2016.
• In August, more than 200 people in the Helsinki Metropolitan Area contracted 
gastroenteritis caused by EHEC and EPEC bacteria. EHEC and EPEC strains corresponding to 
patient samples were found in dishes containing rocket salad that were served at events in 
which the patients had participated.  
• A water-borne epidemic found in Äänekoski in October originated in an air valve unit that 
contained the air vents for both household water and sewage. Some 400 households were 
exposed to the contaminated water. 
• While the incidence of Clostridium difficile cases has remained relatively stable over the last 
six years, variations between different hospital districts remain significant.
• More than one half of EHEC infections had been contracted in Finland. Hemolytic-uremic 
syndrome was diagnosed in eight of the patients, and it was suspected that ten people had 
contracted the infection on a farm.
• There has been a clear increase in domestic campylobacter infections in recent years. The 
reason for this is not known.
• There has been a clear increase in the number of listeriosis cases since 2009. Five clusters of 
a few cases were confirmed by means of whole genome sequencing. 
FOOD- AND WATER-BORNE  
OUTBREAKS
Municipal outbreak investigation working groups 
report suspected food- and water-borne outbreaks 
to the electronic register (RYMY) maintained 
by the National Institute for Health and Welfare 
and the Finnish Food Safety Authority Evira. In 
2016, 89 notifications of suspected cases were en-
tered in the RYMY system (2015: 52). The Nation-
al  Institute for Health and Welfare contacted the 
municipal outbreak investigation working group 
with regard to 21 notifications. Several other gastroin-
testinal infection clusters were confirmed as well.
In January, 28 people contracted gastroenteritis at a 
sports institute in Western Finland. The symptoms, 
duration of the illness, incubation period and laborato-
ry findings indicated that the epidemic was caused by 
norovirus. An employee of the sports institute became 
ill simultaneously with the customers, and norovirus 
GI.P3 was identified in the employee’s stool sample. 
Customers of the sports institute, their family members 
and institute employees had already displayed symp-
toms of gastroenteritis before the epidemic was detect-
ed. Consequently, the infections may have been con-
tracted from contaminated surfaces. 
An epidemic caused by Salmonella Enteritidis was 
confirmed in Pirkanmaa in March‒May: the typing re-
sults of strains in 22 patients were a match. The results 
of a survey and tracing of products indicated that bean 
sprouts of a foreign origin were the probable source of 
the infections. The seed batches of these sprouts were 
recalled in the Finnish market. 
GII. P16/GII.2, a new type of norovirus, caused a 
wide-spread gastroenteritis epidemic on a cruise ship 
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in May‒June 2016. A questionnaire study indicated 
that more than 250 passengers and staff members had 
contracted the infection. The response rate among pas-
sengers was as low as 8%, and it is thus likely that the 
number of passengers who fell ill was considerably 
higher. The infections spread through contact transmis-
sion, and passengers who became ill on the ship main-
tained the contamination of surfaces. Additional clean-
ing and disinfection as well as isolation of cabins were 
started immediately after the epidemic was detected, 
and passengers were informed of the importance of 
hand hygiene.
In August, more than 200 people in the Helsinki Met-
ropolitan Area contracted gastroenteritis caused by 
EHEC and EPEC bacteria. None of them were hos-
pitalised. In laboratory tests, 31 EHEC and 62 EPEC 
infections were confirmed. Several different EHEC 
and EPEC strains were isolated in the patients (EHEC 
ONT:H11, EHEC O166:H28, EPEC O111:H8-, EPEC 
O171:H25 and EPEC ONT:H21). EHEC ONT:H11 and 
EPEC O111:H8  strains matching the patient samples 
were found in dishes containing rocket salad served at 
events in which the patients had participated. By means 
of a questionnaire study, a link was established between 
eating foods containing rocket leaves and contracting 
gastroenteritis. The rocket leaves had been sold in ca-
tering packs around Finland. The epidemic originated 
from events organised by a catering company operating 
in the Helsinki Metropolitan Area. 
A water-borne epidemic detected in Äänekoski in Oc-
tober originated in an air valve unit that contained the 
air vents for both household water and sewage. A pipe 
breakage in the system led to a pressure drop, as a con-
sequence of which sewage leaked into the domestic 
water pipes. Some 400 households were exposed to 
the contaminated water. In the early phase of the epi-
demic, sapovirus was diagnosed in patients, and in tests 
conducted due to prolonged symptoms, Dientamoeba 
fragilis protozoa were confirmed. The extent of the ep-
idemic was investigated by means of a questionnaire 
study. The analysis of the survey results remains in-
complete. 
CLOSTRIDIUM DIFFICILE
Of the 5,224 cases of Clostridium difficile report-
ed in 2016, 97% involved a toxin-producing strain 
or toxin gene findings. Women accounted for 57%, 
people aged 75 or over for 47%, and under 15- 
year-olds for 4% of the cases; 2% concerned under 
2-year-olds. The age and gender distributions have re-
mained similar for a number of years. The incidence 
of the infection was 92/100,000 inhabitants. This figure 
has remained relatively stable for the last 6 years (94 to 
101/100,000). Differences in incidence between hospi-
tal districts remained significant (59 to 183/100,000). 
The hospital districts may be going through different 
stages of the epidemic, but differences may also be 
found in the use of antimicrobials, the rate of sam-
ple-taking, the methods used and the actions taken to 
control infections. 
Findings were reported by 22 laboratories, the four 
largest once submitting over one half of these reports. 
The rising trend in the use of nucleic acid detection 
tests, which started in 2014, continued in the selection 
of laboratory methods: the proportion of these tests in-
creased in 2014‒2016 (34–60–74%). There was a cor-
responding decline in the use of cultures. In 2013, 90% 
of the findings were cultured, but in 2014‒2016, only 
52%, 39% and 23% of the findings were obtained using 
this method. Most laboratories still have capabilities 
for using cultures, however, which allows the typing 
of the strains, for example in case of a suspected ep-
idemic. The proportion of antigen findings remained 
unchanged from the previous year (10%).  
The National Institute for Health and Welfare types 
strains related to suspected epidemics and severe 
individual cases. The 1,771 strains typed in 2008‒2015 
represent 146 different ribotypes, of which almost 
one half were sporadic, or individual strain types. The 
range of the most common ribotypes has remained rela-
tively stable, and an international ribotype name is giv-
en to over 90% of the strains. The remainder are given 
a Finnish type name. The proportion of ribotypes 027 
and 001 has declined, while the percentage of ribotypes 
078 and 002 has increased. Of interest have also been 
strains with a toxin gene profile similar to the so-called 
hypervirulent ribotype 027 (A, B and binary toxins, 
18bp deletion in the tcdC gene) but with a different ri-
botype profile. They include ribotypes 016, 134 ja 176 
which, however, remain rare.
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Figure 6. Cases of Clostridium difficile by hospital district and by year, 2008–2016 (no. of cases).
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ENTEROHEMORRHAGIC  
ESCHERICHIA COLI (EHEC)
A total of 144 cases caused by enterohaemorrhagic 
Escherichia coli (EHEC) were reported to the Nation-
al Infectious Diseases Register. The number of EHEC 
infections almost doubled from the year before (2015: 
74).  The incidence was 2.7/100,000 inhabitants across 
the country, and the highest incidence was recorded in 
the 0 to 4 age group (7.0/100,000).  The highest number 
of cases was reported in the Helsinki and Uusimaa Hos-
pital District (incidence 5.4/100,000). A wide-spread 
EHEC epidemic occurred in the area, in which rocket 
salad was confirmed as the cause of the infection (see 
a more detailed description in the section on Food- and 
water-borne outbreaks).
There has been a clear increase in the number of EHEC 
infections since 2013. Changes in the laboratory diag-
nostics of EHEC explain the higher number of infec-
tions: it is likely that the increasing number of PCR 
tests has also resulted in higher sensitivity in detecting 
epidemics. The reporting criterion of EHEC cases is a 
microbe finding confirmed by culture. Since the PCR 
test was introduced, some PCR findings not confirmed 
by culture have also been reported to the National In-
fectious Diseases Register; in 2016, ten of such findings 
were reported.
60% (87) of the infections were classified 
as being of domestic origin. Since 2014, in-
formation on symptoms and exposure relat-
ing to EHEC infections of domestic origin has 
been collected using an electronic interview form 
completed by municipal officials responsible for in-
fectious disease control. The interview data indicates 
that eight patients were diagnosed with hemolytic 
uremic syndrome (HUS). Ten EHEC infections had 
suspected links to contact with a farm, and in two cases, 
identical EHEC O157 strains were found in the patients 
and samples taken from the farm. 
In compliance with the Communicable Diseases Act, 
laboratories attach a microbe strain or a sample to 
their EHEC notifications. The bacterial cultures of 86 
(64%) EHEC cases were sent to the National Institute 
for Health and Welfare’s laboratory and confirmed us-
ing the PCR test. Strains of serotype O157:H7 caused a 
total of 28 cases (33%). Seven O157 strains fermented 
sorbitol. Eighteen of these strains were positive for both 
stx1 and stx2 genes (all of stx subtype 1a, 2c), while 
ten had the stx2 gene only (seven strains of stx sub-
type 2a and three strains of stx subtype 2c). The O157 
strains were divided into seven phage types, PT 8 
 
being the most common.  Three clusters of infection 
with four to five cases each caused by the O157 strain 
were diagnosed by whole genome sequencing. One of 
the clusters was caused by a sorbitol-positive strain.
There were 58 cases of serogroup Non-O157. In total, 
21 serogroups were diagnosed, of which 13 only with 
the WGS method. The most common serogroups were 
O26 (8 strains), O55 (4), O103 (4) and O145 (4). The 
most common stx subtypes were stx2a and stx1a. Three 
clusters of infection with three to ten cases each caused 
by the non-O157 strain were diagnosed by WGS: O145, 
O55 and NT. Ten of the strains linked to the epidemic 
caused by rocket salad and three other strains could not 
be serogrouped by the traditional method based on ag-
glutination or WGS. 
The strains of six HUS cases were obtained for typ-
ing. Three were caused by serotype O157:H7, two by 
O26:H11 and one by O55:H7. All strains were positive 
for the eae gene, five had an stx subtype 2a, and one 
had an stx subtype 2c.  
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Figure 7.  EHEC cases by year, 2007–2016 (no. of cases).
CAMPYLOBACTER
Campylobacter is the most common bacterial cause 
of gastrointestinal infections in Finland.  In 2016, 
4,637 findings of campylobacter were reported 
(2015: 4,589). Campylobacter jejuni was by far the 
most common type of campylobacter (3,928), while 
331 cases of C. coli were reported. The type was not 
specified in 122 cases. 
The incidence in the entire population was 85/100,000. 
Men accounted for 54% of the cases. The highest 
number of infections was reported in the 25 to 29 age 
group (incidence 144/100,000). Incidence was highest 
in the Helsinki and Uusimaa Hospital District (inci-
dence 120/100,000). Seasonal variation was typical for 
campylobacter, as the incidence was highest in July–
August. 
In 45% of the cases, data was lacking on the country of 
acquisition. Of the infections, 21% (974) were of do-
mestic origin. The number of domestic infections has 
increased clearly since 2010. The reason for this is not 
known. More information on the sources of campylo-
bacter infections would be necessary to target preven-
tion measures.    
Whole genome sequencing was used for laboratory 
testing of strains that were linked to suspected infec-
tions contracted from unpasteurised milk in July and 
a water-borne epidemic in August. The C. jejuni strain 
in a patient who had consumed unpasteurised milk was 
found to be similar to the strains isolated in fecal sam-
ples from bovines on the farm that produced the milk 
and in an environmental sample. Two C. jejuni strains 
linked to the water-borne epidemic in patients were 
confirmed to be identical, but no campylobacter were 
found in the water. 
LISTERIA
In 2016, a total of 67 systemic infections caused by 
the bacterium Listeria monocytogenes were diagnosed 
(2015: 46). Of these patients, one half were aged 74 
or over, and 57% (38) were women. The listeria cases 
were spread out across the country, excluding one hos-
pital district. For the time being, information on preg-
nancy is not being reported to the National Infectious 
Diseases Register. However, one pregnancy-related 
listeria infection was diagnosed based on an interview 
with the patient. Upon the introduction of electronic 
notification of infectious diseases by physicians, sur-
veillance data for listeriosis will also be specified. 
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There has been a clear increase in the number of listeri-
osis cases since 2009. The reason for this is not known. 
Listeria infections are food-borne, and foods with a 
high risk include animal and plant based products and 
ready-made foods that are refrigerated for long periods. 
Listeria bacteria may occur in food production environ-
ments and contaminate a product after the heat treat-
ment that is part of the production process. In Finland, 
foods with a particularly high risk include dry-cured 
and cold smoked fish products. In 2010, dry-cured 
salmon was confirmed as the source of an epidemic, 
and in 2012, an epidemic was caused by aspic. 
The L. monocytogenes strain isolated from the blood 
and/or cerebrospinal fluid of 65 patients arrived for 
typing at laboratory. Of these strains, 44 (67%, in 2015: 
82%) were of serogroup IIa, two of serogroup IIb, five 
of group IIc ja 14 of group IVb. The strains represent-
ed 27 MLST types, the most common ones of which 
were ST206 (6 strains), ST37 (5) and ST9, ST18, ST6 
and ST1 (4 strains each). Five clusters of at minimum 
three cases each were confirmed by whole genome se-
quencing. The largest ones were serotype IIa, MLST 
206 (6 cases in January–November) and serotype IVb, 
MLST 6 (4 cases in September‒December). Strains 
from both clusters were additionally found in early 
2017. Five EPIS (Epidemic Intelligence Information 
System) queries from ECDC concerning listeria were 
received. Three of these strains were compared to the 
Finnish strains based on sequencing or PFGE. None 
of the strains occurred in Finland. PFGE comparisons 
were not anymore carried out after the first quarter of 
the year.   
SALMONELLA
In 2016, a total of 1,505 salmonella cases were re-
ported (2015: 1,656), of which 55 % were detect-
ed in women. The annual incidence in the entire 
country was 28/100,000. The incidence was high-
est in the Helsinki and Uusimaa Hospital Dis-
trict (36/100,000) and the lowest in the East Sa-
vo Hospital District (0.5/100,000). The highest 
number of infections was reported in the 20 to 24 
age group. S. Typhi, which causes typhoid fever, 
was identified in three persons. Two cases of S. Para-
typhi (Paratyphi A), which causes paratyphoid fever, 
were found. All patients had been travelling in Asia. 
The bacterial strain of a total of 1,474 cases of sal-
monella was sent to the National Institute for Health 
and Welfare. The number of strains was lower 
than in the previous year (1,583). Of these strains, 
1,183 (80%) were of foreign and 259 (18%) of do-
mestic origin. In 33 (2%) cases, the origin of the 
salmonella infection remained unclear.
Domestic salmonella infections were caused by 50 dif-
ferent serotypes. The three most common ones, including 
Enteritidis (83 cases), Typhimurium (55) and group B 
(22), caused 62% of the infections. Most (68%, 2015: 
80%) cases were still susceptible to all 12 antimicrobi-
als tested, and the proportion of multiresistant strains 
increased from the previous years’ level to the level 
typical of earlier years (2016: 19%; 2015: 12%; 2014: 
20%; 2013: 21%).
The number of domestic cases caused by the En-
teritidis serotype increased from previous years 
(83, 2015: 59) and they were less often suscepti-
ble to all of the antimicrobials tested (45%, 2015: 
80%). Enteritidis strains were divided into 16 
different phage types, the most common one being PT1 
(31%). These changes were due to the bean sprout re-
lated epidemic in Pirkanmaa, as the cause of which was 
confirmed multiresistant Enteritidis PT1, MLVA 3-13-
5-4-1. 
Of the domestic Typhimurium strains, only 7% were 
multiresistant (2015: 6%). The Typhimurium strains 
were divided into 10 different phage types. The pro-
portion of the domestic phage type PT1 (27%) was in 
the same range as in the year before (2015: 29%).  The 
PT1 strains were susceptible to antimicrobials, except 
one strain.
The number of domestic group B cases (22) has sta-
bilised after an increase that took place a few years 
ago. The majority of group B strains were so-called 
monophasic S. Typhimurium strains (20 cases). Almost 
all monophasic Typhimurium strains isolated from in-
fections of domestic origin were multiresistant; most 
commonly to ampicillin, treptomycin, sulfonamide and 
tetracycline.
This resistance gives us reason to suspect that the 
monophasic Typhimurium strains are actually of 
foreign origin, e.g. secondary cases related to someone 
who returned from abroad or originating in an imported 
food product. Multiresistant monophasic Typhimurium 
strains are not known to occur in domestic farm ani-
mals. The most common monophasic phage type has 
varied in previous years (PT7A, PT120, PT195). In 
2016, the most common type was PT193 (11/20).
The leading countries of acquisition in cases of for-
eign origin were Thailand (29%), Turkey (11%), Spain 
(6%), Greece (5%) and Indonesia (5%). The number 
of strains from the WHO/European countries decreased 
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from the year before (424 compared to 577), while the 
number of strains originating outside the WHO/Euro-
pean countries increased from the previous year (791 
compared to 661). Of foreign strains, 11% were sero-
typed, including all invasive strains and a few strains 
where identifying the species was problematic.
Table 1. The most common serotypes of salmonella cases of domestic origin, 2007–2016 (excluding S. 
Typhi and S. Paratyphi), no. of cases.
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Domestically acquired infections (Source: National Institute for Health and Welfare, Bacterial Infections Unit)
Salmonella Enteritidis 62 48 51 44 47 83 46 49 59 83
Salmonella Typhimurium 156 85 140 132 94 98 94 92 79 55
Salmonella group B 11 5 7 8 40 35 38 32 30 22
Salmonella Infantis 3 7 2 9 10 36 12 9 10 7
Salmonella Senftenberg 1 2 5 5 1 1 3 1 6
Salmonella Stanley 11 8 6 7 1 3 1 6 6 6
Salmonella Java 0 0 0 0 2 0 2 5 13 6
Salmonella Newport 28 71 9 8 6 7 11 9 27 5
Salmonella Thompson 0 3 2 12 2 5 9 6 0 4
Salmonella Napoli 2 0 2 0 6 3 7 2 2 4
Salmonella Saintpaul 2 6 2 2 0 5 4 4 6 4
Salmonella Kottbus 1 0 3 2 0 0 0 1 3 4
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Figure 8. Salmonella and campylobacter cases by month, 2007–2016 (no. of cases).
SHIGELLA
In 2016, the incidence of shigellosis was 
1.2/100,000. The total number of cases reported 
was 66 (2015: 92).  Of these, 36 were in men, and 
the median age was 40 years (variation 1 to 85). The 
majority of the cases (68%) were reported in the Hel-
sinki and Uusimaa Hospital District. Seven hospital 
districts had no diagnosed cases. The lack of findings in 
so many hospital districts gives reason to suspect prob-
lems in the primary diagnostics of shigella, which is 
known to require particular care.   
The shigella strains of 61 persons were sent to the Na-
tional Institute for Health and Welfare’s laboratory. Of 
the total number, 52 infections (85%) were reported as 
having been acquired abroad and nine in Finland, and 
in one case the country of acquisition was not reported. 
As in the previous year, the most common countries of 
origin continued to be Thailand (5 cases) and India (5 
cases). A total of 32 strains (52%) were typed, includ-
ing all infections of domestic origin and a sample of 
the foreign ones. The prevailing shigella species were 
Shigella sonnei (19) and Shigella flexneri (10). The ma-
jority (27 species, 84%) were multiresistant (resistant 
to at least three of the 12 antimicrobials tested). All do-
mestic strains were multiresistant. 
YERSINIA
Yersinia findings are reported to the National Infectious 
Diseases Register under the Communicable Diseases 
Decree, which does not, however, require that Yersin-
ia strains be sent to  the National Institute for Health 
and Welfare. The institute only types Yersinia strains 
in special circumstances, including epidemics or severe 
infections. 
Yersinia enterocolitica
In 2016, 547 cases of Yersinia enterocolitica were re-
ported to the National Infectious Diseases Register 
(2015: 560). The incidence in the entire country was 
10/100,000, with the highest incidence in the 25 to 
29 age group (18/100,000). Regional variation in Y. 
enterocolitica findings was great. The incidence was 
highest in the hospital districts of Helsinki and Uusi-
maa (16/100,000), North Ostrobothnia (14/100,000) 
and Satakunta (11/100,000). One Y. enterocolitica case 
was reported in the Åland. Information on the country 
of acquisition was not provided in 67% of the reports 
(365/547). 
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Y. enterocolitica is most commonly identified from a 
stool culture. In 2016, the number of cases confirmed 
by culture totalled 512, while 45 cases were identified 
by antibody findings in serum. Fourteen cases were 
identified by two different methods (PCR and culture 
or culture and antibody typing). Y. enterocolitica find-
ings were reported by 15 laboratories. Of these, ten also 
reported the biotype and/or serotype, or the results of a 
virulence plasmid test, at least occasionally. The typing 
result was given in 48% of the cases: 67% (178/264) 
were of the biotype BT1A, 21% of the biotype/sero-
type BT4/O:3, and 8% of the type BT2/O:9. BT 1A is 
a heterogeneous group of strains that lack the pYV vir-
ulence plasmid typical of pathogenic yersinias. How-
ever, some BT 1A strains may have other properties 
affecting their pathogenic capabilities. 
Yersinia pseudotuberculosis
In 2016, the number of Yersinia pseudotuberculosis 
cases was 23 (2015: 16). The incidence for the entire 
country was 0.4/100,000 inhabitants. Unlike previous 
years, more cases were confirmed by antibodies (18) 
than by culture (5). The numbers of cases were too low 
to describe regional differences. In earlier years, epi-
demics have caused variations in the annual incidence 
of Y. pseudotuberculosis cases. 
NOROVIRUS
In 2016, 2,395 cases of norovirus infection were re-
ported to the National Infectious Diseases Register, or 
slightly more than in 2015 (2,164). Notifications were 
submitted by all hospital districts and, as in previous 
years, the majority in January‒May (1,652, 69%). 
Cases occurred in all age groups, but almost one half 
(47 %) of them in persons over 75 years of age. The 
percentage of women was 58%. 
Norovirus is one of the most common causes of food- 
and water-borne epidemics. In 2016, 41/89 (46%) 
suspected epidemics in which the suspected pathogen 
was norovirus were reported to RYMY, the national 
outbreak notification system of the National Institute 
of Health and Welfare and the Finnish Food Safety Au-
thority Evira.
In 2016, the National Institute for Health and 
Welfare typed norovirus samples from 16 epi-
demics. Genotype GII.Pe was found in two ep-
idemics in early 2016. The genotype GII.e has 
developed through mutations from the globally 
highly common genotype GII.4, detected in Finland 
for the first time in 2008. In late winter 2016, a virus 
strain of a new type, GII.P16-GII.2, was found in five 
epidemics occurring in different parts of Finland. Gen-
otype GII.Pg caused two reported epidemics. Other 
types of norovirus found in 2016 included GI.2, GI.3 
and GII.7.
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Figure 9. Cases of norovirus infection by month, 2007–2016 (no. of cases).
ROTAVIRUS
In 2016, 150 cases of rotavirus were reported to the 
National Infectious Diseases Register. The number of 
cases has remained below 500 since the rotavirus vac-
cine was introduced to the national vaccination pro-
gramme in 2009. Comprehensive rotavirus vaccinations 
for young children have clearly decreased the incidence 
of rotavirus infections in under 5-year-olds (2016: 
23/100,000) in comparison with the average incidence 
(460/100,000) in this age group prior to the vaccination 
programme. A continuously increasing percentage of 
cases occur in patients aged 5 and older (2016: 55 %), 
whereas the percentage of such cases before the vacci-
nations was  approximately 10%. More than one half of 
rotavirus cases in children under 5 years of age occurred 
in unvaccinated individuals. 
The National Institute for Health and Welfare maintains 
the microbial strain collection of rotaviruses in accor-
dance with the Communicable Diseases Act and Decree 
and is monitoring whether the virus strains that have re-
duced due to vaccination are being replaced by other 
virus strains. Rotavirus positive findings sent by clini-
cal laboratories to the National Institute for Health and 
Welfare are typed on the basis of molecular genetics by 
the University of Tampere Vaccine Research Center. In 
2016, the most common type of rotavirus that caused 
outbreaks of cases was G9P[8], and the next most com-
mon rotavirus types in Finland were G1P[8], G2P[4], 
G3P[8] and G12P[8]. The total number of G3P[8] find-
ings was 16. None of these were zoonotic. Increasingly 
rare viruses have been circulating in Finland, including 
the reassortant animal and human strain G6P[8] and the 
G29P[9] strain that may be of animal origin.
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Figure 10. Rotavirus cases by age group in children aged 0 to 4, 2007–2016 (no. of cases).
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Hepatitis
• Only six cases of hepatitis A infection were reported to the National Infectious Diseases 
Register, which was fewer than ever before.
• A significantly lower number of chronic hepatitis B infections was reported than in 
the previous year. As in earlier years, the majority of the infections were diagnosed in 
foreigners. 
• The majority of patients infected with hepatitis C in Finland were intravenous drug users. 
HEPATITIS A
In 2016, only six hepatitis A cases were reported 
(0.1/100,000), which was less than ever before. Three 
of the infections had been contracted abroad. The low 
number of cases is likely to be due to the good vaccine 
protection of travellers and risk groups. In 2013‒2015, 
27 to 41 cases were reported. Extensive international 
food-borne epidemics had an impact on the large case 
numbers.
HEPATITIS B
Acute hepatitis B
In 2016, 11 (0.2/100,000) acute cases of hepatitis B, 
i.e. ones that tested positive for IgM antibodies, were 
reported to the National Infectious Diseases Register. 
Three of the infected patients were of Finnish and eight 
of foreign origin. The mode of transmission was report-
ed in three cases only, and in each one of these, it was 
sexual contact. In one of the cases, it was sex between 
men. The country of acquisition was reported in four 
cases: in two cases it was Finland and in the other two 
a foreign country.
Over the last ten years, the reported annual average 
number of acute hepatitis B infections has been 20, 
whereas in the record year of 1998, almost 180 infec-
tions were reported. This decrease is mainly due to 
higher vaccination coverage. Moreover, needle and 
syringe exchange has probably prevented infections 
among users of intravenous drugs.
Vaccination of risk groups began in Finland in the 
1990s. In 2016, the national vaccination programme 
was extended to include the following groups: 1) chil-
dren aged under 5 at day care centres when it is known 
that one of the children in the group is HBsAg positive, 
2) newborns when at least one of the parents comes 
from a country where hepatitis B is widespread, 3) 
newborn children of mothers infected by hepatitis C, 
4) men who have sex with other men. The vaccination 
coverage has also been improved by individuals who 
get the vaccination at their own cost, which has been 
especially popular among travellers. 
Chronic hepatitis B
In 2016, 341 chronic hepatitis B infections were report-
ed (6.2/100,000), which is some 50 cases less than the 
year before. Most infections (65%) were found in men. 
The majority (90%) were diagnosed in foreigners. The 
country of acquisition was known in 42% of the cas-
es, in 92% of which the infection had been contracted 
abroad. The mode of transmission was only reported 
in 9% of the cases, with sexual contact and perinatal 
infection being the most common ones. 
Almost one half (46%) of the infections were found in 
persons who did not have a Finnish personal identity 
code. This is partly explained by the fact that asylum 
seekers arriving in Finland are screened for hepatitis 
B, and the diagnoses of the over 30,000 asylum seek-
ers who arrived as a result of the refugee crisis in 2015 
continued to be reported in 2016.
The number of chronic hepatitis B cases has decreased 
since the peak year of 1996, in which more than 600 
cases were reported. The reason for this is a dramatic 
drop in cases reported in Finnish patients. A similar de-
crease has not been recorded in infections contracted 
by foreigners.
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HEPATITIS C
In 2016, 1,147 (21/100,000) new cases of hepatitis C 
were reported to the National Infectious Diseases Reg-
ister, on a par with previous years. The highest num-
ber of infections (33%) was reported in the Helsinki 
and Uusimaa Hospital District, where the incidence 
was 23/100,000. The highest incidences were record-
ed in the hospital districts of Länsi-Pohja (35/100,000), 
Kymenlaakso (32/100,000) and South Karelia 
(29/100,000) and the lowest in the hospital districts of 
Central Ostrobothnia (9/100,000), South Ostrobothnia 
(13/100,000) and Åland (14/100,000). 
Of these patients, 67% were men, and the cases were 
most frequent in the age group 20 to 39, account-
ing for 69% of all cases. The incidence was highest 
(78/100,000) in the age group 20 to 24. The majority 
of infections (86%) were diagnosed in individuals of 
Finnish origin. The country of acquisition was known 
in 57% of the cases. Of these, the majority (88%) were 
infections contracted in Finland. 
Intravenous drug use was the most common method of 
infection (51%). Information on the mode of transmis-
sion was lacking in 40% of cases. Sexual contact was 
given as the mode of transmission in six per cent. Of 
these cases, 59% were diagnosed in women. Five infec-
tions were reported as being acquired through sexual 
contact between men. 
The majority of hepatitis C infections was reported 
without a personal identity code in 1995‒1997. The 
high figures for hepatitis C in 1996–2000 (1,800 cases 
on average per year) may have been partially due to 
cases without personal identity codes being registered 
several times, and the probable registration for those 
years of most cases initially diagnosed before surveil-
lance began. Since 2003, the annual number of cases 
has varied between 1,100 and 1,200, the lowest figure 
being recorded in 2009 (1,042). 
In all, some 30,000 cases of hepatitis C have been re-
ported to the National Infectious Diseases Register in 
1994–2016. However, the total number of those infect-
ed and carriers is unknown because the prevalence of 
hepatitis C has not been studied at population level in 
Finland. The number of carriers is growing, however, 
because the number of new infections is clearly higher 
than the number of cases treated.
The majority of infected patients in Finland are in-
travenous drug users. A very high percentage, 
around 75%, of intravenous drug users have been 
found to have hepatitis C antibodies. Because of 
this, it is difficult to reduce the number of infections 
further in this group by means of the current nee-
dle and syringe exchange programmes alone. In 
2016, the Ministry of Social Affairs and Health pub-
lished the first Finnish hepatitis C strategy http://urn.
fi/URN:ISBN:978-952-00-3845-8. The strategy aims 
for more effective prevention of new infections, har-
monisation of testing and treatment practices, bringing 
infected patients within the scope of comprehensive 
monitoring and treatment, more effecting surveillance 
of infections and the disease situation, and creating a 
treatment monitoring system. The long-term objec-
tive of the strategy is treating all hepatitis C carriers, 
regardless of the degree of damage to their livers, and 
decreasing the incidence of hepatitis C and the number 
of chronic carriers of the virus. 
Table 2. All cases of hepatitis C according to physicians’ reports, by mode of transmission, 2007–2016 (no. 
of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Injecting drugs 478 589 530 641 627 663 652 704 619 590
Sex 72 82 75 83 90 69 91 86 78 76
Perinatal 3 10 10 11 12 8 5 4 3 2
Blood products 24 20 5 14 8 7 11 13 14 6
Other 41 47 50 40 31 42 36 39 25 25
Unknown 575 430 416 380 403 406 380 393 428 458
Total 1,189 1,173 1,083 1,179 1,180 1,185 1,181 1,236 1,181 1,157
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Figure 11. Hepatitis C by age group, 2007–2016 (no. of cases).
Figure 12. Incidence of hepatitis C (cases/100,000 population) by hospital district, 2016.
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Sexually transmitted diseases
• A record-breaking number of chlamydia and gonorrhoea infections was reported in 2016.
• Most gonorrhoea and syphilis infections in persons of Finnish origin were acquired in 
Finland.
• A significant percentage of HIV, gonorrhoea and syphilis infections contracted by men were 
the result of sexual contact between men.
• One half of HIV infections are diagnosed late.
CHLAMYDIA 
(CHLAMYDIA TRACHOMATIS)
In 2016, a total of 14,311 cases of chlamydia were di-
agnosed (262/100,000), which exceeds the previous 
year’s number by more than 700 and is the largest an-
nual number reported to the National Infectious Dis-
eases Register so far. This increase may partly be ex-
plained by the possibility of taking samples at home, 
which reaches new target groups for testing. The high-
est number of cases (34%) was reported in the Helsinki 
and Uusimaa Hospital District but, as in the previous 
year,  the incidence was highest (338/100,000) in the 
Hospital District of Lapland. 
Typically for chlamydia, most cases were diagnosed in 
women and young adults: 59% of the infections were 
reported in women and 80% in the age group 15 to 29. 
The incidence was highest (1,750/100,000) in the age 
group 20 to 24. The age groups in which infections oc-
cur most frequently are younger among women than 
among men. Almost 80% of infections in the age group 
15 to 19, and slightly more than 60% in the age group 
20 to 24, were reported in women. In the age group 25 
and over, on the other hand, the proportion of men is as 
a rule some 10% higher than the proportion of women. 
The majority (92%) of infections were diagnosed in in-
dividuals of Finnish origin. 
LGV  
(LYMPHOGRANULOMA VENEREUM)
Eight cases of LGV, which is caused by Chlamydia 
trachomatis, were reported in 2016. Six of the patients 
were of Finnish and two of foreign origin. As the mode 
of transmission was reported sexual contact between 
men in all cases. Five of the infections were contracted 
abroad and three in Finland. 
Reporting of LVG cases began in 2011. All in all, 27 in-
fections have been reported, all in men and 22 in Finns. 
The mode of transmission is known in all cases but 
one, being sexual contact between men in all of them.
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Figure 13. Chlamydia cases in the young adult age groups, 2007–2016 (no. of cases).
GONORRHOEAE 
(NEISSERIA GONORRHOEA)
In 2016, a total of 416 cases of gonorrhoea were diag-
nosed (7.6/100,000), which exceeds the previous year’s 
number by 135 and is the largest annual number report-
ed to the National Infectious Diseases Register so far. 
The number of cases increased in both men and wom-
en, with both groups showing an increase of some 50% 
compared to the year before. The increase in diagnosed 
infections may partly be explained by more effective 
testing: a combination test for chlamydia and gonor-
rhoea is used more widely, and taking the sample at 
home is now possible.
The highest number of infections, accounting for 65% 
of all cases, was reported in the Helsinki and Uusimaa 
Hospital District, where the incidence was also highest 
(16.8/100,000). As in previous years, the majority of 
infections (76%) was reported in men. Most cases oc-
curred in the age group 20 to 35, accounting for slightly 
more than one half of all cases. The incidence was high-
est (25.2/100,000) in the age group 25 to 29. The major-
ity of infections (77%) were diagnosed in individuals of 
Finnish origin.
The country of acquisition was reported in 82% of cas-
es. Of these, the majority of infections in both Finns and 
foreigners had been contracted in Finland (66%). As in 
previous years, the majority (26) of the infections con-
tracted abroad originated in Thailand.
The gender of the sexual contact was reported in 72% 
of the cases in men. The percentage of sexual contact 
between men was significant (64%). Most infections 
where the mode of transmission was sex between men 
were contracted in Finland, and the majority of the cas-
es were reported in the Helsinki and Uusimaa Hospital 
District.
In most cases, the infection is diagnosed by nucleic 
acid detection. Antimicrobial susceptibility was only 
known in about one half of the gonorrhoea cases in 
2015. No Gonococcus strains resistant to ceftriaxon 
had been reported in Finland by the end of 2015 (Finres 
2015, http://urn.fi/URN:ISBN:978-952-302-716-9). 
SYPHILIS 
(TREPONEMA PALLIDUM)
In 2016, 232 syphilis infections were diagnosed 
(4.3/100,000). While this is slightly less than the year 
before, it however is the second largest annual num-
ber reported to the National Infectious Diseases Reg-
ister. The figure includes both active infections and old 
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 serological scars. Since 2016, an effort has been made 
to distinguish between these two. However, the stage of 
the illness was only reported in 13% of cases.
Almost one half (44%) were reported in the Helsinki 
and Uusimaa Hospital District. The highest incidence 
was reported in the South Karelia Hospital District 
(9.1/100,000).
As in previous years, the majority of infections (77%) 
were reported in men. The cases were most frequent 
in the age group 25 to 49, which accounted for 67% of 
all cases. The incidence was highest (10.7/100,000) in 
the age group 40 to 45.  Individuals of foreign origin 
accounted for 58% of the cases. It is likely that the ma-
jority of these concerned serological scars.
The country of acquisition was reported in 67% of all 
cases. Infections acquired in the home country domi-
nated in individuals of Finnish origin with 77%.
The gender of the sexual contact was reported in 54% 
of the cases in men. The percentage of sexual contact 
between men was significant: 57% of infections among 
men were contracted in this way. Of these, two out of 
three had been acquired in Finland.
HIV AND AIDS
In 2016, 183 new HIV infections were diagnosed 
(3.4/100,000). More than one half, or 55%, were re-
ported in the Helsinki and Uusimaa Hospital District, 
where the incidence was also highest (6.2/100,000). 
Twenty-seven new cases of AIDS were diagnosed. In 
20 of these, a HIV infection had also been diagnosed 
in 2016. 
Most HIV infections (68%) were found in men. The 
proportion of Finnish men was significantly higher 
than that of foreign men (88% compared to 47%). In-
dividuals of foreign origin accounted for 60% of the 
infections. The cases were the most frequent in the age 
group 25 to 49, accounting for 71% of all cases. The 
incidence was highest (8.7/100,000) in the age group 
35 to 39. At the time of diagnosis, the average age of 
Finnish patients was clearly higher than that of foreign-
ers (48 compared to 36 years).
The mode of transmission was reported in 74% of all 
cases. The majority of infections (90%) were acquired 
through sexual contact. In the total number of infec-
tions, the share of heterosexual contact was 58%, sex 
between men 32%, injecting drugs 3%, blood products 
3% and mother to child infections 1%.
Seventy-eight infections acquired through heterosexu-
al contact were reported. The most cases were report-
ed in men (58%) and persons of foreign origin (58%). 
The country of acquisition was known in 84% of cas-
es; 78% of these were acquired abroad. As in previous 
years, Thailand was a prominent source of infection for 
Finns who had acquired the infection abroad.
The number of infections acquired through sexual en-
counters between men was 44. Of these, individuals 
of Finnish origin accounted for 61%. The country of 
infection was known in 88% of cases: of these, approx-
imately one half had been acquired in Finland and one 
half abroad. Two thirds of cases among Finns were 
contracted in the home country, however.
Six cases were diagnosed in which the infection was re-
lated to intravenous drug use, all of these in individuals 
of foreign origin. Since the epidemic at the turn of the 
millennium, efficient prevention methods have helped 
to keep the number of infections contracted in Finland 
at a low level.
One mother to child infection acquired abroad was re-
ported. Because of comprehensive screening at mater-
nity clinics and efficient HIV medication, no mother to 
child infections have been diagnosed in Finland since 
2000. 
In five cases, all in foreigners, blood products were re-
ported as the source of infection. However, in four out 
of these cases, sexual contact was also mentioned as 
a possible mode of transmission. Since HIV testing of 
donated blood began in Finland in 1985, no cases of 
infection through blood products have been reported in 
Finland.
In 2016, 27 new cases of AIDS were reported, two 
thirds of these in individuals of Finnish origin. The ma-
jority of these were related to a late diagnosis of a HIV 
infection. The CD4 value at the time of diagnosis was 
reported in 74% of the cases. The percentage of late 
detection of infections (CD4 lower than 350) was 52%. 
The challenge therefore lies in detecting HIV infections 
earlier than at present, thus preventing the development 
of AIDS and the spread of infections. 
By the end of 2016, the total number of HIV infections 
diagnosed in Finland was 3,734. The reported number 
of HIV positive patients who died was 471, with 28 
deaths in 2016. Because of efficient HIV medication, 
the majority of deaths in the 2000s were due to reasons 
other than HIV.
Infectious Diseases in Finland 2016THL – Report 11/2017 
34
Figure 14. No. of gonorrhoea cases by gender,  2007–2016.
Figure 15. No. of syphilis cases by gender,  2007–2016.
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Figure 16. HIV cases by mode of transmission, 2007–2016 (no. of cases).
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Antimicrobial resistance
• The number of MRSA infections, and also that of blood cultures, was significantly higher 
than in the previous year.
• The percentage of MRSA findings increased in the 20 to 24 age group, and the number of 
MRSA cases in children also went up.
• While the number of VRE cases increased from the year before, no blood culture findings 
were made.
• The total number of E. coli ESBL findings increaced from the previous year.
• While the number of CPE findings remains relatively low in Finland, it has continued to 
increase since surveillance began in 2009. In recent years, three clusters of infections caused 
by KPC-3 positive K. pneumoniae (ST512) in care institutions have been found in Finland.
• More than one half of the CPE infections had probably been acquired abroad.  
MRSA
In 2016, 1,700 new cases of MRSA (methicillinre-
sistant Staphylococcus aureus) were reported, con-
siderably more than in the year before (2015: 1,274). 
The number of MRSA cases confirmed through blood 
culture findings was also higher than in the previous 
year (2016: 49; 2015: 40). Of the MRSA blood cul-
ture findings, 23 were in the Helsinki and Uusimaa 
Hospital District (1.4/100,000) and six in Pirkanmaa 
(1.1/100,000), while the other hospital districts report-
ed zero to two cases, totalling 20. Most (30/49) inva-
sive cases occurred in men and in the 65 and over age 
group (32/49), while three occurred in children. The 
total number of cases was highest in the hospital dis-
tricts of Helsinki and Uusimaa  (604) and Pirkanmaa 
(291), and the incidence was highest in Pirkanmaa 
(55/100,000) and Päijät-Häme (51/100,000). Unlike 
before, a larger percentage of the findings were made in 
the age group 20 to 24 (2016: 26%, 2015: 18%), while 
a smaller proportion was in those aged 65 and over 
(2016: 34%, 2015: 39%). The number of MRSA cases 
in children also increased (2016: 194, 2015: 140).
Patients arriving at hospital are screened for MRSA 
if they have been in a refugee camp or hospitalised 
abroad in the last 12 months. In 2016, 374 patients who 
did not have a Finnish personal identity code were di-
agnosed as MRSA carriers (2015: 161 findings). This 
group is highly likely to include not only tourists but 
also a significant number of asylum seekers.
The MRSA strain was typed in 1,796 individuals. There 
were 262 different spa types among the MRSA strains 
(2015: 247; 2014: 205). The three most common spa 
types were the same as in previous years, albeit in a 
slightly different order: t008 12% (2015: 8%, 2014: 
11%), t172 10% (2015: 16%, 2014: 19%) and t067 8% 
(2015: 6%, 2014: 10%). The next most common spa 
types were t304 7%, t223 4%, t127 4% and t044 4%.
Of these, in particular t304 (2015: 4% 2014: 1%), t223 
(2015: 3% 2014: 2%) and t127 (2015: 4% 2014: 2%) 
have increased their prevalence significantly in the last 
two years.  In the same period, the prevalence of spa 
type t386 has increased from a few sporadic cases in 
2014 to the top ten of the most common spa types in 
2016 (2016: 3%, 2015: 2%, 2014: 0%).
t008 was present in 16 hospital districts, and t172 in 
14 different hospital districts. Unlike previous years, 
the occurrence of spa type t067 was most frequent in 
the Helsinki and Uusimaa Hospital District, in which 
a cluster caused by this strain was detected. The sec-
ond highest occurrence of spa type t067 was reported 
in Pirkanmaa where, after a few years with a declining 
trend, the strain occurred more frequently than in the 
year before. 
The two most common spa types among patients aged 
75 and over were t008 19% (2015: 7%), t067 17% 
(2015: 12%) and t172 13% (2015: 21%). The most 
common spa types among children under the age of 
16 were t304 13% (2015: 5%), t223 12% (2015: 5%), 
t002 7% (2015: 5 %) t008 7% (2015: 7%) and t386 6% 
(2015: 3%).
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An invasive MRSA strain was typed in 45 individuals. 
The most common spa types were : t008 (2016: 9 and 
2015: 6), t067 (2016: 6 and 2015: 0), t172 (2016: 4 and 
2015: 10) and t437 (2016: 3 and 2015: 0). There were 
two cases each of spa types t020, t034 and t304, and 
the remaining cases (17/45) each represented different 
spa types.
In 2016, five MRSA strains with the mecC gene were 
isolated from clinical samples (2015: 4), all of which 
represented spa type t843.
Spa types of the MRSA CC398 complex related to pro-
duction animals were found in the samples of 49 indi-
viduals.  In 2016, it accounted for 2.9% of new MRSA 
cases (2015: 3.2%, 2014: 1.3%).
Spa type t034 is clearly the most common strain of the 
CC398 complex in Finland (2016): 37/49) (2015: 33, 
2014: 14, 2013: 5, 2012: 2). So far, there have been five 
MRSA CC398 findings in blood in Finland (2016: 2 
t034; 2015: t034 and t1250; 2013: t12593). Other spa 
types of the CC398 complex found in Finland include 
t011, t108, t571, t899, t1250, t1255, t2582, t2741 and 
t12593.
Table 3. MRSA findings and their percentage of S. aureus blood culture findings, 1995–2016 
(no. of cases and %).
Year MRSA findings S.aureus blood culture findings MRSA blood culture findings and S.aureus 
methicillin resistance (%)
1995 89 627 2 (0.3)
1996 110 667 0 (0.0)
1997 121 747 4 (0.5)
1998 190 719 5 (0.7)
1999 212 813 8 (1.0)
2000 266 850 4 (0.5)
2001 340 887 4 (0.5)
2002 600 989 9 (0.9)
2003 859 981 7 (0.7)
2004 1,479 1,059 30 (2.8)
2005 1,374 1,013 27 (2.7)
2006 1,331 1,240 37 (3.0)
2007 1,254 1,179 33 (2.8)
2008 1,728 1,260 40 (3.2)
2009 1,266 1,289 30 (2.3)
2010 1,267 1,374 26 (1.9)
2011 1,328 1,484 43 (2.9)
2012 1,287 1,492 30 (2.0)
2013 1,282 1,590 29 (1.8)
2014 1,342 1,925 46 (2.4)
2015 1,274 2,051 40 (2.0)
2016 1,700 2,209 49 (2.2)
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Figure 17. MRSA cases by hospital district and by year, 2007–2016 (no. of cases).
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VRE
The number of reported cases of vancomycin resistant 
enterococcus (VRE) in 2016 increased from the previ-
ous year (2016: 71, 2015: 13). The highest number of 
findings were made in the hospital districts of North 
Karelia (22), North Ostrobothnia (21) and Helsinki and 
Uusimaa (13). In the other hospital districts, the num-
ber of findings varied from zero to three. None of the 
findings were based on a blood sample, and in general, 
VRE has rarely been found in blood (2015: 1, 2014: 0, 
2013: 0).
In total, 71 VRE findings were sent to the microbial 
strain collection, of which 66 were of the species En-
terococcus faecium (44 vanA, 25 vanB) and five were 
E. faecalis (3 vanA, 2 vanB). A cluster of 19 patients 
caused by vanA positive E. faecium (ST17) was found 
in the North Karelia Hospital District. vanB-positive E. 
faecium (ST780), on the other hand, infected a clus-
ter of 15 patients in the North Ostrobothnia Hospital 
District. A cluster of five patients caused by vanA pos-
itive E. faecium (ST80) was found in the Helsinki and 
Uusimaa Hospital District. In addition, two small local 
clusters of two patients and one cluster of three patients 
were found. The remainder of the typed strains (26/71) 
were isolated findings.
In 2016, all VRE strains were for the first time typed 
using whole genome sequencing (WGS). This method 
based on investigating the entire genome of bacteria 
replaces the former PFGE typing method (pulsed-field 
gel electrophoresis) in confirming clusters and investi-
gating epidemics.
ESBL –  ESCHERICHIA COLI AND  
KLEBSIELLA PNEUMONIAE
Since the beginning of 2008, third-generation Esche-
richia coli and Klebsiella pneumoniae exhibiting  re-
duced susceptibility or resistance to cephalosporin (I 
for intermediate and R for resistant, respectively) have 
been reported to the National Infectious Diseases Reg-
ister. An estimated 90 percent of these bacteria are ex-
tended-spectrum beeta-lactamase-producing cephalo-
sporins and so-called ESBL strains producing enzymes 
that degrade all penicillins.
In 2016, the majority of findings were E. coli (4,690; 
in 2015: 4,175), and a small minority were K. pneumo-
niae strains (407; in 2015: 288). E. coli ESBL findings 
were made in all age groups, 73% in women and one 
half in patients aged 65 or over. More than one half of 
the findings (56%) were based on urine cultures. While 
the largest number of cases was found in the Helsinki 
and Uusimaa Hospital District (1,452, 90/100,000), the 
incidence was highest in the hospital districts of Ky-
menlaakso (153/100,000) and Åland (135/100,000). 
The number of blood culture findings exceeded the 
figures for 2015 (286 compared to 232) (the propor-
tion of ESBL in E. coli blood cultures: 286/4,966, 5.8% 
compared to the figure in 2015: 5.1%). Of these, 29% 
were in the Helsinki and Uusimaa Hospital District 
(5/100,000). However, the incidence of blood culture 
findings was highest in the hospital districts of South 
Savo, Länsi-Pohja, Kainuu and Kymenlaakso (9–
10/100 000).
One half of ESBL findings involving K. pneumoni-
ae were diagnosed in patients aged 65 and over but, 
at 61%, the percentage of women was smaller than in 
E. coli ESBL findings. Less than one half of diagno-
ses (41%) were based on urine. The largest number of 
cases was recorded in the hospital districts of Helsinki 
and Uusimaa (113) and Southwest Finland (52), while 
the incidence was highest in the hospital districts of 
Lapland, Kymenlaakso and Southwest Finland. Twen-
ty-seven of the findings (2015: 15) were based on blood 
(the ESBL proportion in K. pneumoniae blood cultures: 
2016: 27/770, 3.5% compared to 2015: 2.3%).
After a short-lived drop, the increase in the number of 
E. coli findings exhibiting resistance to third-generation 
cephalosporin seems to continue in Finland. In younger 
age groups, the steady increase in resistance continued, 
which indicates continuing growth in the percentage 
of carriers within the population. As a whole, the inci-
dence in blood and cerebrospinal fluid findings contin-
ued to grow. 
In 2016, an E. coli ESBL finding was made in 316 in-
dividuals with no Finnish personal identity code (2015: 
194 findings), and a K. pneumoniae ESBL finding in 
32 (2015: 23 findings). This increase may partly be ex-
plained by the screening of bacteria resistant to antimi-
crobials in patients arriving in hospital, including not 
only tourists but probably also a significant number of 
asylum seekers.
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Table 4. E. coli findings with reduced  susceptibility to third-generation cephalosporins (possible ESBL, 
extended-spectrum β-lactamase) and ESBL percentage, 2008–2016 (no. of cases and %).
ESBL findings E. coli blood culture findings ESBL E. coli blood culture findings and 
percentage of ESBL E. coli (%)
2008 1,674 2,814 43 (1.5)
2009 2,177 2,989 77 (2.6)
2010 2,559 3,226 111 (3.4)
2011 3,138 3,475 149 (4.3)
2012 3,686 3,463 203 (5.9)
2013 4,464 3,876 233 (6.0)
2014 4,190 4,366 232 (5.3)
2015 4,175 4,532 232 (5.1)
2016 4,690 4,966 286 (5.8)
Table 5. K. pneumoniae findings with reduced susceptibility to third generation cephalosporins (possible 
ESBL, extended-spectrum β-lactamase) and ESBL percentage, 2008–2016, (no. of cases and %).
ESBL findings K. pneumoniae blood culture 
findings
ESBL K. pneumoniae blood culture findings and 
percentage of ESBL K. pneumoniae (%)
2008 116 418 3 (0.7)
2009 156 480 6 (1.3)
2010 190 508 16 (3.1)
2011 242 453 10 (2.2)
2012 242 583 10 (1.7)
2013 238 570 12 (2.1)
2014 307 634 20 (3.2)
2015 288 670 15 (2.3)
2016 407 770 27 (3.5)
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Figure 18. Incidence of E. coli findings (cases/100,000 population) with reduced susceptibility and resi-
stance to third-generation cephalosporins (possible ESBL, extended-spectrum β-lactamase) by age group 
2008‒2016.
Figure 19. Incidence of E. coli findings (blood and cerebrospinal fluid findings /100,000 population) with  
reduced susceptibility and resistance to third-generation cephalosporins (possible ESBL, exteded- 
spectrum β-lactamase) by age group 2008‒2016.
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CPE (CARBAPENEMASE-PRODUCING 
ENTEROBACTERIA)
In 2016, 63 findings were reported to the National In-
fectious Diseases Register showing enterobacteria with 
reduced susceptibility (intermediate, I) or resistance 
(resistent, R) to carbapenemase, i.e. the bacterial strain 
was possibly CPE. Of the findings, 27 were Esherich-
ia coli, 17 Klebsiella pneumoniae and 19 Enterobacter 
cloacae. In 33 cases, the bacterial strain was sent to 
the laboratory of the National Institute for Health and 
Welfare for further tests. Of these strains, 24 were con-
firmed as actual CPE strains. In addition, 118 possi-
ble CPE strains were sent to the National Institute for 
Health and Welfare, of which 12 proved to be carbap-
enemase-producing. The total number of confirmed 
CPE findings was 36, or slightly more than in 2015. 
Most findings involved E. coli strains (17), while K. 
pneumoniae was also common (14). In addition to 
these, other individual species of enterobacteria with 
the carbapenemase gene were isolated, including two 
Citrobacter freundii strains with the carbapenemase 
gene (KPC-2). The most common carbapenemases 
were KPC-3, NDM-5 and OXA-48. The majority of 
CPE strains were isolated in colonisation samples. The 
median age of patients was 53.
More than one half of the CPE infections had probably 
been acquired abroad.  In 2013–2016, three clusters of 
infections caused by KPC-3 positive K. pneumoniae 
(ST512) in care institutions have been found in Fin-
land. One transmission of a KPC-2 positive C. freundii 
strain from patient to patient was found. 
K. pneumoniae is the most common finding (approx-
imately 53%). Findings to be reported to the National 
Infectious Diseases Register (K. pneumoniae, E. coli 
and E. cloacae) account for 92% of all CPE findings. 
While the number of CPE findings remains relatively 
low in Finland, it has continued to increase since sur-
veillance began in 2009. In particular, an increase has 
been recorded in carbapenemase-producing strains 
NDM and OXA-48. In most cases, these involve E. co-
li.
Table 6. Carbapenemase-producing enterobacteria (CPE), 2009–2016, (no. of cases).
CPE findings 
Year New bacterial strains New patients
2009 5 5
2010 8 8
2011 12 11
2012 9 8
2013 21 20
2014 17 14
2015 29 29
2016 36 34
Table 7. Carbapenemase-producing enterobacteria (CPE) in 2016, (no. of cases).
Carbapenemase Citrobacter  
freundii
Enterobacter  
aerogenes
Enterobacter 
cloacae
E. coli K. pneumoniae
KPC-2 2 1 1
KPC-3 8
NDM-1 1 4
NDM-5 8
NMC-A 1
OXA-244 2
OXA-48 1 6 1
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Tuberculosis
• The number of tuberculosis cases was smaller than in 2015. 
• All children who contracted tuberculosis were of foreign origin.
• The percentage of foreigners among patients contracting tuberculosis was 46%, which was 
a small increase year-on-year.
• The number of drug-resistant Mycobacterium tuberculosis strains has increased slightly in 
recent years.
TUBERCULOSIS 
(MYCOBACTERIUM TUBERCULOSIS)
Incidence of tuberculosis in 2016
The number of tuberculosis cases was 231 
(4.2/100,000), 40 (15%) less than in 2015 (271; 
5.0/100,000). Of these, 170 (74%) were cases of pul-
monary tuberculosis, 54 (32%) of which produced a 
positive sputum stain test. There were 184 cases of tu-
berculosis confirmed by culture (80%), 31 less than in 
2015 (215). 
The increase in the number of tuberculosis cases in Fin-
land in 2007 and 2008 compared to 2006 can be ex-
plained by the introduction in 2007 of the broader EU 
definition of tuberculosis cases. The annual numbers of 
cases confirmed by culture are comparable throughout 
the monitoring period. 
The distribution of cases by age group was as follows: 
6 (2%) in the age group under 15, 66 (29%) in the age 
group 15 to 29, 35 (15%) in the age group 30 to 44, 24 
(10%) in the age group 45 to 59, 47 (20%) in the age 
group 60 to 74, and 53 (23%) in patients aged over 75. 
Population reduction among the age groups in whose 
youth the incidence of tuberculosis in Finland was high 
and the increasing number of young immigrants have 
led to a notable decrease in the average age of tuber-
culosis patients between 2000 and 2016, from 64 to 50 
years.  In 2016, all six children who were diagnosed 
with tuberculosis were of foreign origin.
The patient was reported to be foreign in 106 of all cas-
es (46%), i.e. born abroad and assumed to have other 
than Finnish citizenship unless the data indicate oth-
erwise. This was one more than the year before. Of 
the cases, 68 (64%) had pulmonary tuberculosis, and 
38 (36%) other forms of tuberculosis. Information on 
the patient’s country of birth or citizenship was missing 
in 10 cases (4%). Thirty-eight cases (16%) were diag-
nosed in  individuals who did not have a Finnish per-
sonal identity code. The majority of these are asylum 
seekers.
In five (2%) of the tuberculosis cases reported in 2016, 
the patient also had an HIV infection. In three of these 
cases, the HIV infection was reported as a new case in 
2016, while the HIV infection of the two other patients 
had been registered before. Two of the patients were of 
Finnish and three of foreign origin.
Tuberculosis strain susceptibility to medica-
tion in 2016
Although susceptibility to medication is still fair-
ly good, the number of Mycobacterium tuberculosis 
strains resistant to tuberculosis medication has grown. 
Of all cultured strains, 91% had full susceptibility and, 
in 17 cases, resistance to one or several drugs was di-
agnosed. Of the six MDR cases diagnosed during the 
year, one case was an extended-drug resistant (XDR) 
tuberculosis. One of the MDR cases was in a patient 
born in Finland, while the others were from Somalia, 
Eritrea and Afghanistan. Four MDR cases were diag-
nosed in asylum seekers.
Tuberculosis genotyping findings 2016
M. tuberculosis strains were analysed using the inter-
nationally standardised spoligotyping and MIRU-VN-
TR methods, and whole genome sequencing was also 
used in investigations of epidemics. The most common 
spoligotypes were SIT53 (18 strains) and the so-called 
Beijing type SIT1 (16 strains). Seventy-two (39%) 
strains belonged to a cluster sharing the same spoli-
go and MIRU-VNTR type. No major clusters were 
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 observed in 2016, as each cluster consisted of no more 
than four strains. One MDR-TB strain represented a 
cluster found among asylum seekers in the EU area, 
and one XDR-TB strain was linked to mass exposure 
in Romania.
Tuberculosis outcome  surveillance in 2011–
2015
Table 9 shows the distribution of treatment outcomes 
between 2011 and 2015. Cases where the pathogen is 
an MDR strain are reported separately and are not in-
cluded in Table 9. An outcome evaluation is performed 
12 months after the case is registered. 
A significant number (130) of outcome evaluation re-
ports for 2015 were missing when the annual report 
was written, but the treatment outcome was good in 
76% of the cases in 2015 (75 cases). This falls clearly 
short of the international target set by WHO at 85%, 
but is on a par with the average for most EU Member 
States. Mortality (before beginning treatment or during 
treatment) was 19% in 2015.
Other mycobacteria
A total of 617 non-tuberculotic, environmental myco-
bacteria were identified (incidence 11.3/100,000). The 
most common of these found in patient samples were 
Mycobacterium gordonae (163), Mycobacterium avium 
(149) and Mycobacterium intracellulare (63). Seven of 
these were diagnosed in children under the age of 5.
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Table 8. Incidence of tuberculosis  (cases/100,000 population) and percentage of culture-confirmed cases in Finland, 1995–2016 (no. of cases and %).
Pulmonary tuberculosis Other tuberculosis All cases Foreigners
Cases Incidence Cases with 
positive 
sputum 
smear
Incidence Cases Incidence Cases Incidence Culture-con-
firmed
Culture-
conf.%
Cases %
1995 436 8.6 243 4.8 223 4.4 659 12.9 472 71.6 30 4.6
1996 451 8.8 243 4.7 206 4.0 657 12.8 511 77.8 36 5.5
1997 359 7.1 188 3.7 214 4.3 573 11.4 440 76.8 43 7.5
1998 399 7.8 207 4.0 213 4.1 612 11.9 493 80.6 50 8.2
1999 399 7.7 183 3.5 193 3.7 592 11.5 506 85.5 41 6.9
2000 372 7.2 225 4.4 170 3.3 542 10.5 455 83.9 42 7.7
2001 316 6.1 155 3.0 182 3.5 498 9.6 416 83.5 58 11.6
2002 297 5.7 136 2.6 178 3.4 475 9.1 394 82.9 44 9.3
2003 293 5.6 147 2.8 122 2.3 415 8.0 351 84.6 39 9.4
2004 233 4.5 127 2.4 102 2.0 335 6.4 291 86.9 33 9.9
2005 269 5.1 137 2.6 103 2.0 372 7.1 324 87.1 41 11.0
2006 206 3.9 99 1.9 90 1.7 296 5.6 271 91.6 47 15.9
2007 229 4.4 93 1.8 118 2.2 347 6.6 251 72.3 67 19.3
2008 213 4.0 105 2.0 127 2.4 340 6.4 246 72.4 46 13.5
2009 289 5.5 94 1.8 124 2.4 413 7.9 303 73.4 116 28.1
2010 225 4.2 85 1.6 92 1.7 317 5.9 250 78.9 101 31.9
2011 232 4.3 84 1.6 92 1.7 324 6.0 252 77.8 80 24.7
2012 194 3.6 83 1.5 82 1.5 276 5.1 223 80.8 81 29.3
2013 213 3.9 92 1.7 58 1.1 271 5.0 204 75.3 87 32.1
2014 196 3.6 80 1.5 64 1.2 260 4.8 213 81.9 86 33.1
2015 195 3.6 62 1.1 76 1.4 271 5.0 215 61.6 105 38.7
2016 170 3.1 54 1.0 61 1.1 231 4.2 184 79.7 106 45.9
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Table 9. Results of outcome evaluation for treatment of microbiologically confirmed pulmonary tuberculo-
sis, 2009–2015 (no. of cases and %).     
2011 2012 2013 2014 2015
Favourable 131 (69%) 164 (98%) 142 (78%) 117 (75%) 57 (76%)
Cured 74 65 82 67 34
Treatment completed 57 59 60 50 23
Non-favourable 38 (20%) 26 (15%) 33 (18%) 29 (18%) 14 (19%)
Deceased 37 26 32 28 14
Interrupted treatment 0 0 0 1 0
Treatment failure 1 0 1 0 0
Unknown 21 (11%) 18 (11%) 8 (4%) 11 (7%) 4 (5%)
Treatment continues at 12 months 8 8 4 5 1
Unknown 13 10 4 6 3
Total 190 168 183 157 75
Figure 20. Tuberculosis cases by age group and origin in 2016, (no. of cases).
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Other infections
• A similar number of severe pneumococcal infections was diagnosed as in the year before.
• The incidence of pneumococcal infection increased slightly in children under 5 due to the 
more frequent occurrence of serotypes not included in the vaccine.
• Since the vaccination programme was introduced, severe pneumococcal infections caused 
by PCV10 vaccine serotypes have been almost totally eliminated in young children, and they 
continued to decline in 2016 especially in adult age groups. 
• Nineteen meningococcal infections were reported, which figure was on a par with the 
previous year. Exceptionally, the majority of these were diagnosed in women. 
• Four measles infections were diagnosed; two of these had been acquired abroad. None of 
the patients had had the MMR  vaccination.
• A total of 1,931 Borrelia cases were reported, which is a slight increase on the record 
number in 2015.  
• Slightly fewer tick-borne encephalitis (TBE) cases were reported than in the peak year of 
2015. In mainland Finland, most TBE infections were contracted in known risk areas.
• More cases of Puumala virus were reported than in 2015. The vole populations increased  
again, especially in Southern and Eastern Finland, which was reflected as a higher number 
of cases.
• More cases of Pogosta disease were reported than in the year before.
• A significant increase in tuleramia cases was recorded compared to recent years; the 
number of these cases exceeded the total number reported in the last six years.
• A total of 60 people were exposed to rabies abroad, most commonly in Indonesia and 
Thailand. Almost one half of the cases of exposure abroad were related to a dog bite, and 
one third to a monkey bite. 
• All cases of malaria, except one, originated in Africa. Approximately one half of the patients 
were immigrants coming from a malarious area who had travelled in their former home 
region. 
• Six infections caused by the zika virus were diagnosed in Finnish tourists.
• The number of cultured blood samples from children has remained unchanged, and slightly 
more than one half of the findings were made in infants aged under 12 months.
• The number of early-onset GBS cases in newborns was record-breakingly low at 11 (0.2 
cases per 1,000 live births). This is probably due to improved preventive practices.
• Almost 16,000 bacterial findings were detected in cultured blood samples from adults. 
These findings have constantly increased, particularly in patients aged 65 or over. 
Escherichia coli was the most common finding in both the working age population and 
in patients aged 65 and over. Other common findings included Staphylococcus aureus, a 
significant percentage of which is known to be treatment-related infections.
• The number of invasive group A streptococcus infections increased in 2016 compared to the 
year before.
Infectious Diseases in Finland 2016THL – Report 11/2017 
48
INVASIVE PNEUMOCOCCAL DISEASE 
(STREPTOCOCCUS PNEUMONIAE)
The number of invasive, severe cases of pneumococ-
cal disease, in which the pathogen was identified in a 
blood or cerebrospinal fluid culture, was 817 (incidence 
15.0/100,000). This equals the figure from 2015 (815; 
14.9/100,000). In addition, the number of cases report-
ed merely on the basis of nucleic acid detection totalled 
nine. No serotype data is available for these cases, and 
they are not included in the statistics below. Of the pa-
tients, 4.0% were under the age of 5 and 50.8% over 
65.
The incidence of pneumococcal disease increased 
slightly in children under 5 due to the higher occur-
rence of serotypes not included in the vaccine.  In 
older children and the adult age groups, the incidence 
did not change (Table 10). As before, the incidence 
was higher in men than in women (16.8 compared to 
13.1/100,000). In some hospital districts, the incidence 
was three times that of others (8.7‒25.5/100,000). This 
may be associated with regional differences in how 
actively blood cultures are taken. The peak period for 
these infections was in December, in which month 137 
cases were reported to the National Infectious Diseases 
Register. It coincided with a high number of influenza 
A cases. 
The serotype of 813 (99.5%) cases of pneumococcal 
disease confirmed by culture was identified. These cas-
es were divided into 36 serotypes or serogroups. Sero-
types 3 and 19A caused approximately one fifth each 
(serotype 3, 167; 20.4% and type 19A, 160; 19.6%) of 
all cases, and serotype 22F caused more than one out of 
ten (101; 12.4%) of all cases (Figure 21). These three 
serotypes were common pathogens, particularly in the 
elderly.  19A was the most common serotype in chil-
dren under 5, in whom it caused 45.5% (15/33) of all 
infections. Together, serotypes 3, 19A and 22F caused 
more than one half (52%) of all cases reported to the 
National Infectious Diseases Register (in 2015, 45%). 
The 10-valent pneumococcal conjugate vaccine 
(PCV10) has been included in the national vac-
cination programme for children since Septem-
ber 2010. Severe pneumococcal diseases caused by 
serotypes in the PCV10 vaccine (1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, 23F) have been almost totally eliminated 
in young children and continued to decrease in 2016, 
particularly in the 18 to 64 and 65 and over age groups 
(Table 11). This is an indirect consequence of the vac-
cination programme for children. In children under 2 
years of age, two cases caused by PCV10 serotypes 
were diagnosed, both in children who had not been 
vaccinated.
The incidence of serotypes not included in the PCV10 
vaccine has increased since the vaccination programme 
was initiated as the vaccine strains were replaced by 
others. In 2016, 85% of all infections were caused by 
serotypes not included in the PCV10 vaccine. The in-
cidence increased year-on-year in all age groups, ex-
cluding those aged over 65, in which group a long-term 
rising trend was halted. For more detailed statistics by 
age and serotype, please see the National Institute for 
Health and Welfare website. 
The Institute no longer tests the pneumococcus bacteria 
sent to its strain collection for antimicrobial sensitivity. 
As before, national statistics on antimicrobial sensitivi-
ty collected from clinical microbiology laboratories are 
published in the annual Finres report.
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Figure 21. Serotypes of Pneumococcus findings in blood and cerebrospinal fluid 2016 (no. of cases).  
The column ”Other” includes serotypes that caused fewer than 10 cases and the column “Unknown” in-
cludes cases whose strains the National Institute for Health and Welfare did not receive.  
PCV10 serotypes, red columns.
Table 10. Pneumococci isolated in blood and cerebrospinal fluid by age groups 2006–2016, no. of cases 
and incidence (cases/100,000 population). 
0—1 2—4 5—17 18—64 65— Total
year Cases I Cases I Cases I Cases I Cases I Cases I
2006 82 71.3 31 18.4 19 2.3 345 10.5 271 32.3 748 14.2
2007 78 67.4 45 26.5 20 2.5 351 10.7 291 33.9 785 14.9
2008 65 55.1 32 18.4 23 2.9 479 14.4 328 37.5 927 17.5
2009 62 52.2 31 17.6 32 4.2 434 13.0 295 33.1 854 16.3
2010 61 50.6 41 23.8 17 2.2 410 12.2 304 33.4 833 15.6
2011 45 37.0 27 15.7 21 2.7 386 11.6 297 31.7 776 14.5
2012 15 12.3 17 9.4 15 1.9 361 10.8 342 34.9 750 13.9
2013 19 15.8 14 7.6 14 1.8 358 10.8 319 31.3 724 13.3
2014 13 11.0 14 7.6 18 2.3 303 9.1 355 33.6 703 12.9
2015 11 9.5 12 6.5 14 1.8 351 10.6 427 39.2 815 14.9
2016 16 14.2 17 9.5 16 2.1 353 10.8 415 37.1 817 15.0
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Table 11. Pneumococci isolated in blood and cerebrospinal fluid by age and vaccine serotypes in 2006–2016, no. of cases and incidence (cases/100,000 
population).
PCV10 vaccine serotypes Non-vaccine serotypes Unknown
0—1 2—4 5—17 18—64 65— Total 0—1 2—4 5—17 18—64 65— Total All age 
groups
year Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I Ca-
ses
I
2006 67 58.3 26 15.4 15 1.8 227 6.9 161 19.2 496 9.4 14 12.2 5 3.0 3 0.4 105 3.2 101 12.5 228 4.3 24 0.5
2007 63 54.5 38 22.4 12 1.5 226 6.9 176 20.5 515 9.8 15 13.0 5 3.0 6 0.8 116 3.5 111 12.9 253 4.8 17 0.3
2008 49 41.5 26 15.0 18 2.2 288 8.7 198 22.6 579 10.9 14 11.9 6 3.5 4 0.5 174 5.2 119 13.6 317 6.0 31 0.6
2009 47 39.6 26 14.8 23 2.9 277 8.3 165 18.5 538 10.3 12 10.1 4 2.3 8 1.0 141 4.2 118 13.2 283 5.4 33 0.6
2010 51 42.3 35 19.7 10 1.3 244 7.3 168 18.5 508 9.5 8 6.6 5 2.8 5 0.6 148 4.4 122 13.4 288 5.4 37 0.7
2011 34 28.0 16 8.9 15 1.9 217 6.5 149 15.9 431 8.0 11 9.5 11 6.1 6 0.8 166 5.0 145 15.5 339 6.3 6 0.1
2012 8 6.6 16 8.8 7 0.9 190 5.7 150 15.3 371 6.9 7 5.8 1 0.6 8 1.3 169 5.6 187 19.9 372 6.9 7 0.1
2013 6 5.0 3 1.6 9 1.2 163 4.9 113 11.1 294 5.4 13 10.8 11 6.0 5 0.7 191 5.7 206 20.2 426 7.9 4 0.1
2014 2 1.7 3 1.6 8 1.3 99 3.0 93 8.8 205 3.8 11 9.3 11 6.0 10 1.3 202 6.9 258 24.4 492 9.0 6 0.1
2015 1 0.9 3 1.6 4 0.5 81 2.5 75 6.9 164 3.0 10 8.6 9 4.9 10 1.3 268 8.1 349 32.0 646 11.8 5 0.1
2016 2 1.8 0 0.0 0 0.0 59 1.8 56 5.0 117 2.1 14 12.5 17 9.4 16 2.1 291 8.9 358 32.0 696 12.7 4 0.1
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HAEMOPHILUS (HAEMOPHILUS 
INFLUENZAE)
The total of 69 (1.26/100,000) infections caused by 
the Haemophilus influenzae bacterium and diagnosed 
in blood or cerebrospinal fluid represent an increase of 
about one third from the average for the last ten years. 
More than a third (24/69, 35%) were diagnosed in 
patients aged 75 years and over, and almost an equal 
amount in the age group 60 to 74 (23/69, 33%). In one 
case, the patient was under 5.
All cases were diagnosed through culture findings, 
mainly based on blood cultures (65/69, 94%). As in 
earlier years, the majority (57/69, 83%) were caused 
by unencapsulated strains of Haemophilus influen-
zae (NTHi). The number of NTHi infections went 
up by approximately one third compared to 2015, 
especially in those aged 75 and over. Only one in-
fection caused by serotype b was found. The pa-
tient was an adult individual in whose childhood the 
Hib vaccine was not yet part of the national vacci-
nation programme. Serotype f caused an infection 
in eight people, one of whom was a 4-year-old child, 
one a 16-year-old and the remainder adults. Serotype 
e caused two infections, both in elderly adults. In one 
case, the National Institute for Welfare and Health did 
not obtain the strain, and its serotype remains unknown. 
Children born in 1985 or later have been given the Hib 
vaccine at their child care clinics. While the vaccina-
tion programme has succeeded in effectively reducing 
the number of serious infections caused by bacteria 
of serotype b and the circulation of the bacteria with-
in the population, cases may still occur in children 
with incomplete vaccination coverage. 
Table 12. Cases of Haemophilus influenzae by serotype in 2007–2016, (no. of cases).
Unencapsulated a b e f Unknown All cases
2007 44 0 6 1 1 2 54
2008 33 0 3 0 8 1 45
2009 30 0 6 2 7 2 47
2010 30 0 5 2 3 1 41
2011 57 0 4 2 2 1 66
2012 73 0 4 0 4 0 81
2013 40 1 1 1 5 0 48
2014 48 0 5 0 6 0 59
2015 40 0 1 2 9 0 52
2016 57 0 1 2 8 1 69
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MENINGOCOCCUS (NEISSERIA 
MENINGITIDIS)
The number of meningococcal infections detected in 
blood or cerebrospinal fluid totalled 19 (0.35/100,000), 
which is on par with the previous three years. Excep-
tionally, the majority of these findings were in women 
(15/19, 79%): in previous years, men usually have had 
slightly more of these infections than women. Of the 
patients, one (5%) was under the age of 3 months, six 
(32%) were aged 16 to 20, and the remainder (12/19, 
63%) were in the age group 25 to 88. It was reported 
that one patient had been in military service when the 
disease was diagnosed. 
Eighteen cases were diagnosed through a bacterial 
culture finding and one through nucleic acid detec-
tion. All bacterial strains were serogrouped and anal-
ysed through full genome sequencing. 6 (33%) were 
of serogroup B, 5 (28%) of serogroup Y, 4 (22%) of 
serogroup C, and three (17%) of serogroup W. The 
serogroup of one case diagnosed through nucleic 
acid detection remained unknown. One of the infec-
tions caused by serogroup B was diagnosed in a child 
aged 3 months, and the remainder in the age group 20 
to 80; 83% (5/6) were in women. Serogroups C, Y and 
W caused infections across the board from young peo-
ple to older age groups (16 to 88); serogroups C and W 
occurred especially frequently in women. Three of the 
serogroup C cases were part of an epidemic found in 
Southern Finland in the autumn that was caused by the 
C:P1.5,2:F3-3:ST-11(cc11) bacteria, which represent 
a hypervirulent clone. No other epidemics or clusters 
were found. 
Except for the serogroup C strain that caused the epi-
demic, most of the bacterial strains were different and 
represented several different types. Serogroup B bacte-
ria represented five different types that were divided into 
three clonal groups. Two types of serogroup C bacteria 
were identified. One of these, or  (C:P1.5,2:F3-3:ST-
11(cc11)), caused the cases associated with the cluster 
in Southern Finland, while the other, or (C:P1.7,16-
29:F3-3:ST-32(cc32)), occurred in an isolated case in 
Pirkanmaa; in 2015, the latter strain caused two cases 
in Western Finland. The serogroup W strains were di-
vided into three types, two of which were genetically 
close. Both represent the hypervirulent cc11 clone, 
which has become more common in recent years, par-
ticularly in England and Wales, and which caused three 
severe cases in Finland in 2015. However, serogroup 
W meningococcus remains extremely rare in Finland 
(2016: 0.05/100,000). There were five different types of 
serogroup Y bacteria, and typically of the strains in this 
group, four of these represented the cc23 clone. 
In sporadic cases of meningococcal infection, all per-
sons in close contact with the patient – except for 
health care personnel – should be given prophylactic 
medication and a vaccination, if infection with the 
strain in question can be prevented by vaccination. Fin-
land has vaccines against the meningococcal serotype 
groups A, C, W and Y. Since the 1970s, the Defence 
Forces have administered a polysaccharide vaccination 
to all recruits. In recent years, cases in conscripts con-
firmed by cultures have been caused by the serogroup 
B, against which the currently used vaccine does not 
give protection. Conjugated meningococcal vaccines 
are mainly used in connection with epidemics and trav-
el. The Defence Forces are also introducing a conjugat-
ed ACWY vaccine, as the polysaccharide vaccination is 
no longer being manufactured. Two new recombinant 
protein vaccines have also been launched in the EU 
market that gives protection against group B meningo-
coccal strains. 
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Table 13. Meningococcal infections by serogroup, 2007–2016 (no. of cases).
A B C W Y Unknown Total
2007 0 29 8 0 5 0 42
2008 0 18 8 0 1 1 28
2009 0 24 3 0 5 1 33
2010 0 14 4 1 13 2 34
2011 0 19 6 1 7 1 34
2012 0 17 3 1 8 4 33
2013 0 10 2 0 8 0 20
2014 0 7 5 1 5 3 21
2015 0 8 5 4 3 2 22
2016 0 6 4 3 5 1 19
MMR DISEASES (MEASLES, 
MUMPS, RUBELLA)
In 2016, the occurrence of diseases prevented by the 
MMR vaccine was slightly higher than in previous 
years in Finland. 
Four cases of measles were diagnosed (2015: 2). Two 
individuals had acquired the infection abroad. Two 
diagnoses were later made in the home town of one 
of these patients, where this individual had been the 
source of infection. None of those who contracted the 
disease had been vaccinated. All the patients were of 
Finnish origin and aged 17 to 44. 
Six cases of mumps were diagnosed (2015: 2). Four of 
the infections had been acquired abroad, while in two 
cases the source of infection remained unclear. Two of 
the patients had received the two MMR vaccinations 
that are part of the vaccination programme as children; 
more than 20 years had elapsed since the latest vacci-
nation had been administered in both cases. One had 
received a single dose of the vaccine more than ten 
years before falling ill, two were unvaccinated, and the 
vaccination history of one was unknown. 
No cases of rubella were diagnosed in 2016.
VARICELLA VIRUS
The number of varicella findings reported to the Na-
tional Infectious Diseases Register was 519 in 2016, 
which corresponds to the previous years’ levels (2013: 
455, 2014: 478, 2015: 505). Virus findings were re-
ported among all age groups, the youngest being one 
month and the oldest 94 years old. Of these findings, 
39% were diagnosed by antigen detection, 31% by nu-
cleic acid detection, and 29% by serological diagnos-
tics. The number of reports based on diagnosis from 
cerebrospinal fluid was 60 (11%). The majority of these 
(90%) involved nucleic acid detection, while the role 
of diagnoses based on antibodies and antigen detection 
was minor.
Childhood varicella or chicken pox is a very common 
disease, with an estimated 57,000 cases in Finland ev-
ery year. Most people contract the infection when aged 
under 5. In most cases, it is diagnosed on the basis of 
symptoms and does not result in a laboratory sample 
being taken. In contrast herpes zoster, or shingles, 
caused by the varicella virus being reactivated, is com-
mon, particularly in the elderly and requires the use 
of health care services, which can be seen in the age 
distribution of the virus findings: the proportion of pa-
tients aged 65 or over in the reported cases was 30%, 
while the percentage of those aged under 5 was as low 
as 10%. 
Varicella vaccination is currently recommended for 
persons in close contact with immunocompromised in-
dividuals and everyone aged 13 or over who has not 
had the chicken pox. The varicella vaccination will be 
included in the national vaccination programme in au-
tumn 2017; in the future, all children will be vaccinated 
at the ages of 18 months and 6 years. Initially, the var-
icella vaccine will be administered to all children aged 
1.5-12 years who have never had chickenpox. 
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BORRELIA (LYME DISEASE)
The laboratories reported a total of 1,931 Borrelia find-
ings in 2016, which is a slight increase on the record 
number in 2015 (1,912). Of these reports, 8 were based 
on nucleic acid detection, 1,895 on a serological test, 
and 28 on a combination of these methods. Cases were 
reported in all parts of the country. While the average 
incidence was 35/100,000, regional variation was con-
siderable. As in previous years, the incidence was high-
est in Åland (2,114/100,000), the 613 cases diagnosed 
there accounting for almost a third of all cases of Bor-
relia in Finland. As before, the frequency of Borrelia 
was highest in the autumn, the majority of cases oc-
curring from August to October. The majority of cases 
(76%) were diagnosed in patients aged 45 and over. No 
differences between genders were observed. The Bor-
relia findings in the National Infectious Diseases Reg-
ister do not give an up-to-date picture of the borreliosis 
epidemiology, and the cases mainly represent late-stage 
borreliosis. In the early stage, the disease is diagnosed 
based on clinical symptoms, and these cases are report-
ed in the outpatient care register of the public health 
services.
Figure 22. Incidence of Borrelia (cases/100,000 population) by hospital district,  2016.
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TICK BORNE ENCEPHALITIS (TBE)
In 2016, 61 TBE antibody findings were reported to 
the National Infectious Diseases Register, or some-
what less than the record-breaking figure of the year 
before (67). Positive findings were diagnosed in April‒
November, mainly in August. Patients who contracted 
TBE were aged between 4 and 84 (average age 51), and 
one elderly person died.
In order to identify the place of acquisition, the Nation-
al Institute for Health and Welfare interviewed patients 
who had been diagnosed with TBE and/or studied 
their patient records. Six patients contracted TBE on 
the Åland Islands, 49 in mainland Finland, five abroad 
(Estonia, Sweden) and, in the case of one individual, 
the place of infection remained unclear. All residents 
of Åland have been entitled to a TBE vaccination free 
of charge since 2006, and in 2017, these vaccinations 
have also been offered to residents in the municipalities 
of Parainen and Simo. 
In mainland Finland, most TBE infections were con-
tracted in known risk areas: the Turku archipelago (16), 
of which 15 occurred in Parainen; Kirkkonummi (5), 
the Lappeenranta region (3), and the region of Simo 
and Kemi (3). Other places of infection included Lohja 
(3), Espoo (3, more specifically Espoonkartano and 
Matinkylän shore), the Raahe archipelago (2), Helsin-
ki (3, more specifically Karhusaari in one case), Turku 
(2), the Sipoo archipelago (2, Röysy), the Western 
Uusimaa archipelago (1, no further details), Ilomantsi 
(1), Salosaari in Ruokolahti (1), Kaakkuri in Oulu (1), 
Luoto (1) and Rauma (1). Unlike the previous year, 
no diagnosed infections were contracted in the Kotka 
archipelago. Rautjärvi (1) emerged as a potential new 
area of infection.  
The TBE virus was identified in ticks not only in Åland, 
but also in the Turku archipelago and the Lappeenranta 
region decades ago, and in collections performed in the 
following risk areas in recent years: Isosaari in Helsin-
ki, the Kokkola archipelago and Maksniemi in Simo. 
Individual findings have recently also been confirmed 
in traditional lower-risk areas (Tampere region, Ilo-
mantsi).          
If a patient falls ill with meningitis or encephalitis be-
tween May and November, even if he or she has not no-
ticed a tick bite, TBE should be suspected, especially if 
the case occurs in a known high-risk area. Because new 
endemic TBE regions may continue to emerge, howev-
er, the possibility of TBE infection should be consid-
ered even beyond currently known risk areas.
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Figure 23. Cases of TBE by location of acquisition, 2016, and TBE virus findings in ticks, 1996–2016.
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PUUMALA VIRUS
In 2016, a total of 1,662 cases of Puumala virus in-
fection were reported (30.4/100,000), which exceeds 
the figure for 2015 (1,463). The incidence of the virus 
varies depending on the virus reservoir, i.e. the size of 
the bank vole population, following a three- or four-
year cycle, in accordance with the geographical region. 
The previous peaks occurred in 2005, 2008, 2011 and 
2014. The vole populations increased  again in 2016, 
especially in Southern and Eastern Finland, which was 
reflected as a higher number of cases.
Of the patients, 59% were men and most patients 
were of working age. Sixty-four (3.9%) cases oc-
curred in patients under 20 years of age. The incidence 
was the highest in the hospital districts of East Savo 
(203/100,000) and North Karelia (>87/100,000).
Figure 24. Incidence of Puumala virus (cases/100,000 population) by hospital district, 2016.
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POGOSTA DISEASE (SINDBIS VIRUS)
In 2016, 31 cases of Pogosta disease, confirmed by 
antibody testing, were diagnosed in Finland. This ex-
ceeded the previous year’s figure (15). The incidence 
was highest in the Central Ostrobothnia Hospital Dis-
trict (5.1/100,000). Only six cases were confirmed in 
the North Karelia Hospital District, historically a high 
incidence area (3.6/100,000). Almost all (30/31) of the 
patients were in working age (age group 15 to 64), 71% 
were women, and 81% of the cases were diagnosed in 
August–September.
Pogosta disease has previously followed a regular sev-
en-year cycle.  The epidemic peaked in 1981, 1995 and 
2002. In 2009, however, the cycle was not repeated as 
expected, and the number of cases in 2016 remained 
very low compared to years with epidemics. 
TULAREMIA  
(FRANCISELLA TULARENSIS)
In 2016, 699 tularemia cases were reported (incidence 
12.8/100,000). This was a significant increase com-
pared to recent years; the number of these cases ex-
ceeded the total number reported in the last six years. 
The incidence was highest in the hospital districts of 
Central Ostrobothnia (115/100,000) and South Ostro-
bothnia (100/100,000). Most cases were diagnosed in 
August–September (605/699, 87%). The annual inci-
dence of tularemia varies considerably (between 0.2 
and 18/100,000) and local epidemics break out every 
few years, particularly in the regions of Ostrobothnia 
and Central Finland, usually following years with plen-
tiful vole populations.  The weather conditions also af-
fect the number of mosquitoes and thus the scale of the 
outbreaks.
RABIES
Doctors are required to report cases where risk as-
sessment after exposure has led to the administration 
of a course of rabies vaccinations and, possibly, rabies 
immunoglobulin treatment. In 2016, 85 reports were 
made, which was a clear increase on 2015 (40). 
The number of patients who had been exposed while 
travelling abroad was 60 (70%): 16 in Indonesia and 15 
in Thailand. Cases of exposure in the following coun-
tries were also reported: 4 in Russia, 3 in India, 2 in 
Malaysia, 3 in Turkey, 3 in Estonia, 2 in Greece and 2 
in Serbia. Others were individual cases of exposure in 
different countries. 
More than one half of the cases of exposure abroad 
were related to a dog bite (28).  The number of reported 
cases related to a monkey bite was 21, which was a 
considerable increase on 2015 (6). The remaining indi-
vidual cases of exposure abroad related to contact with 
cats, bats and rats. Three of the reports did not specify 
the animal involved.
Twenty-four cases of exposure in Finland were report-
ed, 12 of which were related to bats and the others to 
contacts with a dog or a raccoon dog. Six of the reports 
did not specify the animal involved. No cases of expo-
sure to rabies bait vaccine were reported in 2016.
TRAVEL-RELATED INFECTIONS
Malaria
Malaria was diagnosed in 47 patients in Finland in 
2016. There were 37 cases of Plasmodium falciparum, 
nine cases of P. ovale and a single case of P. vivax. Of 
these infections, 46 (98%) originated in Africa, while 
one was acquired in Afghanistan. Of the patients, 26 
(55%) were immigrants from a malaria area who had 
returned to visit their former home region; 7 (15%) 
were immigrants who had fallen ill immediately after 
arriving in Finland; and one was a visitor to Finland. 
Ten of the patients (21%) were native Finns who had 
taken a trip of less than six months to a malaria region, 
and two were Finns residing in a malaria region. The 
countries of acquisition and risk groups of malaria have 
changed little from previous years. 
One half of the malaria cases were diagnosed in the 
Helsinki Metropolitan Area, while the remainder were 
found in other areas of Finland. Of the malaria patients, 
35 (74%) were treated at university hospitals, while 
12 (26%) were treated at central hospitals. No malaria 
deaths were reported.
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Table 14. Malaria cases in Finland in 2016 by coun-
try of acquisition.
Continent Country Cases
Asia Afghanistan 1
Total 1
Africa Angola 1
Benin 3
South Sudan 2
Ethiopia 1
Gambia 1
Ghana 7
Guinea 1
Cameroon 4
Kenya 4
Democratic Republic of Congo 2
Malawi 1
Nigeria 10
Ivory Coast 1
Rwanda 1
Zambia 4
Sierra Leone 1
Somalia 1
Tanzania 1
Total 46
Grand total 47
Chikungunya
No chikungunya infections were diagnosed in Finnish 
tourists in 2016. The year before, the number of cases 
was seven. In 2016, approximately 350,000 infections 
caused by the chikungunya virus were reported in the 
Caribbean and Americas, clearly fewer than in previous 
years, indicating that the outbreak is abating in this ar-
ea. Outbreaks of minor epidemics were also reported in 
the Pacific islands.
Dengue fever 
The annual number of dengue fever infections has var-
ied between 35 and 90. In 2016, laboratories reported 
66 findings; the majority of which (64/66) occurred 
in the age group 15 to 59. Diagnoses were made at all 
times of the year, the highest number in January–March 
(25) and the lowest in July–September (6). Of the in-
fections, 15 were reported as having been contracted 
in Asia (Thailand 4, Indonesia 5, the Philippines 1, the 
Maldives 1, Bangladesh 1, Vietnam 1 and Laos 1), and 
4 in South America and the Caribbean (Argentina 2, the 
Dominican Republic 1, Mexico 1). Information on the 
country of acquisition is not available for the National 
Infectious Diseases Register in all cases.
Zika virus
In 2016, six infections caused by the zika virus were 
diagnosed in Finnish tourists.  Through intensified sur-
veillance, data on the countries of acquisition and other 
details were obtained. Of the infections, five had been 
acquired in the South and Central American area (Bra-
zil 2, Costa Rica 2, the Caribbean 1), where the zika 
virus was spreading rapidly in 2016. One infection had 
been contracted in Asia (the Philippines). It is likely 
that mosquitoes were the source of all the infections. 
The patients were aged 24 to 39, and 4 of them were 
women. 
Other travel-related infections
A significant percentage of the following infections 
are travel-related:  legionella, salmonella, campylo-
bacter, shigella, EHEC, hepatitis A, hepatitis B, gonor-
rhoea, syphilis, HIV and AIDS, carbapenem-resistant 
gram-negative bacilli, MMR diseases and exposure to 
rabies. Data on the country of acquisition and means of 
transmission is discussed separately for each of these 
diseases in the respective section of this report.
BLOOD AND CEREBROSPINAL FLUID 
FINDINGS IN CHILDREN
Blood culture findings in children
In 2016, 439 cases of bacterial findings were diagnosed 
in blood cultures from children under 15 years of age. 
In comparison with previous years, the number has re-
mained largely unchanged (in 2012−2015: 452 on av-
erage, variation 440−461), whereas in earlier years, the 
number of findings was clearly higher (in 2007–2011: 
608 on average, variation 551–662).
Slightly more than one half of the findings (234/439) 
were made in children aged under 12 months. In in-
fants, Staphylococcus epidermidis and other coag-
ulase-negative staphylococci caused 34% of blood 
culture positive infections (Table 15). Although these 
bacteria belong to normal skin flora, they typically 
cause treatment-related late-onset sepsis in newborn ba-
bies in intensive care. Streptococcus agalactiae (Group 
B streptococcus, GBS), typically contracted from the 
mother’s birth canal during labour and causing an 
infection (early-onset sepsis) in the newborn baby 
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 during its first days of life, caused 9% of the findings. 
The number of Escherichia coli (21% of all findings) 
and Klebsiella (4%) findings had increased clearly 
from previous years. Staphylococcus aureus (9%) and 
Enterococcus faecalis (6%) continued to be other com-
mon causes of infections.
In the age group 1 to 14 years, S. aureus (26%) was 
the most common cause of blood culture positive infec-
tions in 2016 (Table 16). The number of S. pneumoniae 
findings decreased quickly after the introduction of a 
pneumococcus vaccination to the national vaccination 
programme in 2010;  in 2012–2015, 27 to 35 cases were 
diagnosed annually (12–17% of all findings), while in 
2016, the number of pneumococcus findings was 38 
(19%). Other common findings in this age group were 
coagulase-negative staphylococci (19%), E. coli (7%), 
Streptococcus pyogenes (5%) and the Streptococcus 
viridans group (4%).
Fungal findings are rare in children’s blood cultures. 
However, in 2016 Candida albicans was diagnosed in 
two children, and Candida parapsilosis in two children 
aged 0 to 14 based on blood cultures.
Cerebrospinal fluid findings in children
The number of cerebrospinal fluid findings related to 
children’s central nervous system infections remained 
on a par with previous years, as did the distribution of 
pathogens. The total number of findings reported in 
2016 was 14 (in 2007−2015: 28 on average, variation 
22‒37). Eight of these infections were diagnosed in 
children under the age of 12 months.
Bacteria found in the age group under 12 months in-
cluded S. agalactiae, coagulase-negative staphylococ-
ci, E. coli, S. pneumoniae and Neisseria meningitidis 
(Table 17); the findings in the age group 1 to 14 were 
sporadic and included S. pneumoniae and Haemophilus 
influenzae (Table 18). There were no fungal findings in 
cerebrospinal fluid samples.
GBS in newborns
Between 1995 and 2014, an average of 31 cases per 
year of early-onset GBS in newborns (diagnosed 
from blood and/or cerebrospinal fluid in children 
under the age of 7 days) were reported; the variation 
was 17 to 57 cases per year, and the incidence was 
0.3 to 1.0 per 1,000 live births.  In 2015, the number 
of cases was clearly lower: 13 (0.2 cases per 1,000 
live births), and in 2016, as low as 11 (0.2/1,000 live 
births). The majority of early-onset GBS cases can 
be prevented by administering an antimicrobial pro-
phylaxis to mothers whose GBS colonisation puts the 
newborn at risk of a GBS infection. The preventive 
practices have improved in recent years, which is like-
ly to explain the reduction of infections in newborns. 
An average of 14 annual cases of late GBS disease de-
tected at the age of more than 7 days have occurred in 
1995–2015 (range 6 to 24; incidence 0.1 to 0.4 cases 
per 1,000 live births). There were 9 cases in 2016 (0.2 
cases per 1,000 live births). Antimicrobial prophylax-
is during labour does not prevent early-onset GBS in 
newborns.
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Table 15. Blood culture findings in infants (under 12 months), 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Escherichia coli 42 38 37 45 48 25 41 37 38 50
Staphylococcus epidermidis 92 87 64 71 76 50 62 46 49 46
Staphylococcus, other 
coagulase-negative 43 34 43 32 35 26 33 45 34 33
Streptococcus agalactiae 51 49 51 54 42 36 33 31 26 20
Staphylococcus aureus 25 23 22 24 21 31 22 20 28 20
Enterococcus faecalis 8 5 10 20 12 15 16 9 10 13
Klebsiella species 6 7 9 3 7 6 6 4 3 10
Enterobacter species 8 6 3 3 10 5 4 2 7 10
Streptococcus pneumoniae 21 26 25 20 11 8 8 6 6 8
Streptococcus, other beta-
haemolytic 0 0 4 2 0 1 1 1 1 5
Streptococcus viridans 
group 9 8 9 16 13 6 8 8 9 5
Serratia species 3 4 1 2 4 0 1 0 4 2
Pseudomonas aeruginosa 0 2 0 2 1 0 0 0 3 1
Propionibacterium species 1 0 0 0 1 0 0 0 0 1
Neisseria meningitidis 3 3 5 4 1 2 4 3 1 1
Citrobacter species 0 0 1 1 0 1 0 0 0 1
Bacteroides fragilis group 1 1 0 1 0 0 0 0 0 1
Bacillus 4 4 2 1 1 1 1 1 5 1
Acinetobacter 2 1 1 3 2 1 2 0 0 1
Enterococcus faecium 0 1 2 2 1 2 1 1 0 1
Streptococcus pyogenes 3 2 4 2 0 6 1 2 0 0
Streptococcus bovis group 0 0 2 0 0 0 0 0 0 0
Stenotrophomonas  
maltophilia 2 0 2 2 0 0 0 0 0 0
Pseudomonas, other than 
aeruginosa 0 0 0 0 0 0 0 1 0 0
Proteus mirabilis 1 0 0 0 0 0 0 0 0 0
Prevotella species 0 1 0 0 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 1 0 0 0 0 0 0
Listeria monocytogenes 1 0 1 2 0 1 1 1 0 0
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Bacteroides, other than 
fragilis group 0 0 0 0 0 0 0 0 1 0
Yersinia enterocolitica 0 0 0 0 0 0 0 1 1 0
Salmonella, other than 
Typhi or Paratyphi 0 0 1 0 0 0 1 1 1 0
Haemophilus, other than 
influenzae 0 1 0 0 1 0 0 0 0 0
Haemophilus influenzae 1 2 2 1 0 4 1 2 1 0
Enterococcus, other or 
unidentified 0 0 2 0 0 1 0 0 0 0
Clostridium, other than 
perfringens 0 0 0 0 0 1 0 0 0 0
Other bacteria 7 7 5 5 9 8 3 6 5 4
Bacteria total 334 312 308 319 296 237 250 228 233 234
Other candida species 2 1 0 0 1 2 0 1 0 1
Candida albicans 2 3 1 2 1 1 2 3 2 1
Other fungi 0 0 0 0 0 0 0 0 0 0
Fungi total 4 4 1 2 2 3 2 4 2 2
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Table 16. Blood culture findings in children (aged 1 to 14), 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Staphylococcus aureus 42 40 36 43 42 47 48 40 54 53
Streptococcus pneumoniae 115 87 92 95 74 35 35 32 27 38
Staphylococcus epidermidis 33 22 31 37 29 17 25 28 26 22
Staphylococcus, other  
coagulase-negative 19 13 17 21 13 11 9 19 23 17
Escherichia coli 12 14 12 15 11 14 9 17 20 14
Streptococcus pyogenes 13 11 11 6 15 9 8 14 13 10
Streptococcus viridans 
group 21 21 25 37 23 27 27 14 10 9
Streptococcus milleri group 0 2 2 2 1 1 0 2 2 7
Klebsiella species 6 5 2 4 2 6 3 0 1 5
Bacteroides fragilis group 0 0 1 0 2 0 0 1 1 4
Enterococcus faecalis 6 6 4 6 3 5 1 2 3 3
Streptococcus, other beta-
haemolytic 4 0 2 3 1 1 1 1 4 3
Citrobacter species 2 2 1 1 0 0 0 3 0 2
Stenotrophomonas  
maltophilia 3 4 2 2 0 1 1 1 0 2
Clostridium, other than 
perfringens 1 1 1 4 4 1 1 2 0 1
Haemophilus influenzae 2 3 3 2 5 0 3 5 1 1
Bacillus 0 6 3 3 2 5 5 4 6 1
Enterobacter species 2 4 3 2 3 1 0 0 6 1
Propionibacterium species 0 0 0 0 0 2 1 0 0 1
Pseudomonas aeruginosa 2 1 3 7 4 3 4 9 1 1
Serratia species 1 0 0 1 0 0 1 0 0 1
Clostridium perfringens 2 0 1 1 0 0 0 0 0 0
Corynebacterium diphteriae 0 0 0 0 0 0 0 1 0 0
Enterococcus faecium 4 2 7 7 0 2 2 1 0 0
Enterococcus, other or 
unidentified 2 3 0 1 0 0 1 0 0 0
Haemophilus, other than 
influenzae 0 0 0 0 0 1 1 0 1 0
Salmonella Paratyphi 0 0 0 0 0 0 0 0 0 0
Salmonella Typhi 2 0 0 0 2 0 1 0 0 0
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Salmonella, other than Typhi 
or Paratyphi 5 2 0 6 2 3 4 1 1 0
Yersinia enterocolitica 0 0 0 0 0 0 0 0 0 0
Yersinia  
pseudotuberculosis 0 0 0 0 0 0 0 0 0 0
Acinetobacter 2 2 4 1 0 1 3 1 3 0
Bacteroides, other than 
fragilis group 0 0 0 0 0 0 0 0 0 0
Fusobacterium species 5 5 1 1 1 1 1 1 0 0
Listeria monocytogenes 0 0 0 0 0 0 1 0 0 0
Mycobacterium species 0 0 0 0 1 0 0 0 1 0
Neisseria meningitidis 3 4 0 6 2 2 3 1 1 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 2 1 0 0 1 0
Proteus mirabilis 1 0 0 0 0 0 0 0 0 0
Pseudomonas, other than 
aeruginosa 1 0 3 0 0 0 0 0 1 0
Streptococcus  
agalactiae 2 1 0 0 0 0 0 0 0 0
Streptococcus  
bovis group 0 0 0 0 0 0 0 0 1 0
Veillonella species 0 0 0 1 0 0 0 0 0 0
Other bacteria 15 10 13 24 11 14 9 12 20 9
Bacteria total 328 271 280 339 255 211 208 212 228 205
Other candida species 3 1 0 0 3 0 1 0 1 1
Candida albicans 0 2 0 2 0 1 2 1 1 1
Fungi total 3 3 0 2 3 1 3 1 2 2
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Table 17. Cerebrospinal fluid culture findings in infants (under 12 months), 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Streptococcus agalactiae 8 3 6 10 3 4 1 7 3 3
Staphylococcus, other 
coagulase-negative 0 4 1 0 0 2 0 0 0 2
Streptococcus pneumoniae 4 3 2 3 2 1 2 2 0 1
Neisseria meningitidis 2 1 2 1 0 3 3 2 0 1
Escherichia coli 1 1 1 2 1 0 0 2 2 1
Streptococcus, other beta-
haemolytic 0 0 0 0 0 0 0 0 0 0
Streptococcus viridans 
group 0 0 2 0 1 0 0 0 0 0
Streptococcus pyogenes 0 0 1 0 0 0 0 0 0 0
Enterococcus faecalis 1 0 0 0 0 0 0 0 0 0
Staphylococcus epidermidis 2 1 2 2 2 1 3 2 0 0
Staphylococcus aureus 1 2 2 1 0 3 2 1 1 0
Propionibacterium species 0 0 0 0 0 0 0 1 0 0
Mycobacterium species 0 0 0 1 0 0 0 0 0 0
Bacillus 0 0 0 0 0 0 0 1 0 0
Haemophilus influenzae 0 0 1 0 0 0 0 1 0 0
Bacteroides, other than 
fragilis group 1 0 0 0 0 0 0 0 0 0
Klebsiella species 0 0 1 0 0 1 0 0 0 0
Citrobacter species 1 0 0 1 0 0 0 1 0 0
Other bacteria 0 0 1 0 0 0 1 1 0 0
Bacteria total 21 15 22 21 9 15 12 21 6 8
Candida albicans 0 0 1 0 0 0 0 0 0 0
Fungi total 0 0 1 0 0 0 0 0 0 0
Infectious Diseases in Finland 2016THL – Report 11/2017 
66
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Staphylococcus  
epidermidis
1 5 2 1 2 1 0 3 3 1
Streptococcus pneumoniae 5 2 4 2 3 0 4 2 1 1
Streptococcus viridans 
group
0 0 0 0 0 0 0 0 2 1
Propionibacterium species 0 0 0 0 1 0 0 1 2 1
Haemophilus influenzae 0 0 0 0 1 0 0 1 0 1
Enterobacter species 0 0 1 0 0 1 0 0 0 1
Streptococcus, other beta-
haemolytic
0 0 1 0 0 0 0 0 0 0
Streptococcus pyogenes 0 0 0 0 0 1 0 0 0 0
Enterococcus faecalis 0 0 0 1 0 0 0 0 1 0
Staphylococcus, other 
coagulase-negative
0 0 1 0 0 0 1 0 1 0
Staphylococcus aureus 2 3 3 2 2 2 1 0 1 0
Neisseria meningitidis 6 3 2 3 4 2 3 1 2 0
Escherichia coli 0 0 0 0 0 1 0 0 0 0
Other bacteria 0 2 1 1 0 0 1 1 1 0
Bacteria total 14 15 15 10 13 8 10 9 14 6
Candida albicans 0 0 0 0 0 1 0 0 0 0
Fungi total 0 0 0 0 0 1 0 0 0 0
Table 18. Cerebrospinal fluid culture findings in children (aged 1 to 14), 2007–2016 (no. of cases).
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BLOOD AND CEREBROSPINAL FLUID 
FINDINGS IN ADULTS
Blood culture findings in adults
In 2016, the total number of bacterial findings in 
adults’ blood culture samples was 15,907. The number 
of findings has increased continuously, and the year-
on-year increase was considerable (9%). The majori-
ty (69%, 10,921/15,907) of the blood culture findings 
were made in the age group 65 and over. Gram-posi-
tive bacteria were more common in the working-age 
population (aged 15 to 64) and gram-negative bacteria 
among those aged 65 and over. The number of fungi 
findings in adults’ blood cultures has remained stable 
(in 2007–2015, 209 cases on average, variation 174 to 
252). In 2016, a total of 209 findings were made (1.3% 
of all blood culture findings in those aged 15 or over).
Escherichia coli was the most common finding in both 
the working age population (24% of findings) and in 
patients aged 65 and over (34%). Other common bac-
terial findings (Tables 19 and 20) were Staphylococcus 
aureus (working age 17%, aged 65 and over 12%), co-
agulase-negative staphylococci (working age 9%, 65 
and over 7%), Streptococcus pneumoniae (working age 
7%, 65 and over 4%), and Klebsiella species (working 
age 5%, 65 and over 7%). It is estimated that one half 
of Staphylococcus aureus findings and almost all coag-
ulase-negative staphylococci findings are treatment-re-
lated. Anaerobic bacteria constituted around 4% of all 
blood culture positive findings among adults.
Cerebrospinal fluid findings in adults
In 2016, the total number of microbial findings in 
adults’ cerebrospinal fluid was 118, which corresponds 
to their numbers in 2007–2015 (137 on average, varia-
tion 110 to 173). Patients aged 65 and over accounted 
for 38% of the cases. One finding of a fungus was re-
ported. 
In the working-age population, coagulase-negative 
staphylococci accounted for 26% of the findings (Table 
22). The most common actual pathogens were S. au-
reus (18%) and S. pneumoniae (16%). In patients aged 
65 years or older, the most common findings were co-
agulase-negative staphylococci (24%), Listeria mono-
cytogenes (18%), S. pneumoniae (13%), Propionibac-
terium species (9%), and  S. aureus (7%) (Table 23).
Group A streptococcus
The number of invasive group A streptococcus (Strep-
tococcus pyogenes)  infections increased in 2016 com-
pared to the year before (2016: 229 and 2015: 178). 
The two most prevalent emm types of group A strepto-
cocci, or emm28 and emm89, were the same as in pre-
vious years (Table 21). Emm types emm1 and emm4 
occurred at a steady rate. The emm-type that has pre-
vailed for several years, emm12, increased its propor-
tion (2016: 10%; 2015: 5%; 2014: 5%). The numbers 
of macrolide-resistant type emm33 began to decline 
in 2015, and there were no findings in 2016. Although 
new emm types are continuously emerging, the four 
most common emm types – emm28, emm89, emm1 
and emm12 – accounted for 74% of all emm types (Ta-
ble 21).
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Table 19. Blood culture findings in patients aged 15 to 64, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Escherichia coli 837 872 884 931 934 942 951 1070 1113 1182
Staphylococcus aureus 544 526 539 579 641 617 645 800 785 858
Streptococcus pneumoniae 352 479 440 413 391 364 356 307 350 352
Klebsiella species 159 186 189 207 166 218 221 222 206 243
Staphylococcus, other 
coagulase-negative 147 156 139 140 144 104 154 191 209 242
Staphylococcus epidermidis 265 279 313 265 223 182 211 240 270 214
Streptococcus, other  
betahaemolytic 129 128 122 139 154 133 177 173 156 202
Bacteroides fragilis group 82 108 68 110 108 103 101 132 125 164
Streptococcus milleri group 65 73 57 68 86 79 98 127 128 148
Streptococcus viridans 
group 116 137 144 147 157 150 148 129 108 118
Streptococcus pyogenes 133 157 116 113 104 126 105 122 97 118
Enterobacter species 70 69 82 99 86 96 90 85 97 108
Enterococcus faecalis 105 83 107 86 97 102 83 104 110 98
Streptococcus agalactiae 83 96 95 110 75 89 96 89 113 88
Enterococcus faecium 81 91 89 91 108 95 97 113 71 85
Pseudomonas aeruginosa 72 74 78 91 92 79 91 74 81 75
Bacillus 24 25 21 32 34 27 42 60 54 55
Peptostreptococcus and 
Peptococcus 11 12 27 15 30 18 22 38 36 48
Fusobacterium species 31 31 27 37 32 48 41 47 37 39
Serratia species 19 24 27 20 32 26 32 31 39 39
Salmonella, other than 
Typhi or Paratyphi 52 43 23 39 32 32 36 28 25 39
Citrobacter species 19 23 29 31 28 25 23 35 30 37
Campylobacter species 8 7 11 10 4 6 8 33 26 33
Clostridium, other than 
perfringens 18 24 29 23 20 32 29 43 30 28
Haemophilus influenzae 26 18 19 18 22 25 23 18 22 28
Proteus mirabilis 14 14 18 26 17 24 22 23 32 27
Prevotella species 8 13 13 15 16 16 10 12 10 23
Morganella morganii 7 14 8 6 8 7 18 12 13 14
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Propionibacterium species 5 3 9 6 9 7 9 11 8 13
Capnocytophaga  
canimorsus 8 8 11 11 17 13 14 15 12 11
Acinetobacter 21 13 18 14 21 14 11 15 18 11
Listeria monocytogenes 9 8 9 15 7 17 11 18 9 10
Stenotrophomonas  
maltophilia 5 15 12 12 9 7 14 16 20 8
Bacteroides, other than 
fragilis group 3 5 10 1 7 3 7 8 5 8
Clostridium perfringens 12 10 16 16 8 11 8 13 12 7
Neisseria meningitidis 21 9 12 13 17 12 5 10 12 7
Streptococcus bovis group 7 1 6 7 6 6 4 5 8 6
Haemophilus, other than 
influenzae 3 3 0 2 3 10 5 6 8 6
Pseudomonas, other than 
aeruginosa 3 5 6 6 8 8 8 14 11 5
Hafnia alvei 1 3 6 2 2 2 1 2 2 4
Enterococcus, other or 
unidentified 4 7 13 13 12 20 8 5 14 3
Mycobacterium species 5 2 2 2 4 3 8 4 3 2
Salmonella Paratyphi 6 5 3 3 1 3 1 2 2 2
Salmonella Typhi 4 1 3 9 3 1 5 5 1 2
Proteus vulgaris 3 2 3 2 2 3 2 4 4 2
Yersinia enterocolitica 1 0 1 1 0 0 0 0 2 1
Veillonella species 4 3 6 5 12 5 7 8 5 0
Yersinia pseudotuberculosis 0 1 0 0 0 1 1 1 0 0
Other bacteria 78 94 107 92 99 112 131 157 150 173
Bacteria total 3,680 3,960 3,967 4,093 4,088 4,023 4,190 4,677 4,679 4,986
Candida albicans 55 55 55 57 74 56 64 53 47 52
Other candida species 26 41 29 37 34 31 45 44 50 32
Other fungi 4 2 3 1 3 2 3 3 1 1
Fungi total 85 98 87 95 111 89 112 100 98 85
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Table 20. Blood culture findings in patients aged 65 or over, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Escherichia coli 1759 1888 2053 2233 2479 2482 2876 3242 3360 3721
Staphylococcus aureus 568 671 691 729 780 797 876 1065 1184 1278
Klebsiella species 339 381 464 472 476 539 563 675 735 806
Streptococcus, other beta-
haemolytic 181 193 232 279 285 308 335 442 465 527
Staphylococcus  
epidermidis 275 298 271 326 316 300 344 366 394 419
Streptococcus pneumoniae 290 326 294 303 295 342 319 355 425 415
Staphylococcus, other 
coagulase-negative 144 171 161 149 162 170 252 293 367 383
Enterococcus faecalis 220 217 222 229 275 287 301 375 334 372
Bacteroides  
fragilis group 135 146 164 178 203 183 202 253 295 301
Pseudomonas aeruginosa 188 191 184 218 196 250 230 233 253 273
Enterobacter species 105 131 128 156 157 174 188 172 217 257
Enterococcus faecium 132 126 175 180 197 182 209 257 204 200
Streptococcus  
viridans group 113 140 135 132 168 175 191 161 162 195
Streptococcus agalactiae 77 94 104 126 113 117 129 170 162 191
Proteus mirabilis 93 99 102 106 98 130 118 156 150 190
Streptococcus  
milleri group 54 53 62 59 59 65 92 127 144 152
Citrobacter species 35 65 59 76 59 95 100 97 113 129
Serratia species 33 50 37 59 56 64 81 72 89 114
Streptococcus pyogenes 58 50 61 50 49 75 67 73 68 101
Clostridium, other than 
perfringens 33 30 39 44 38 45 39 60 69 82
Peptostreptococcus and 
Peptococcus 25 14 29 36 26 24 32 44 42 71
Clostridium perfringens 39 34 49 40 51 56 34 57 61 68
Listeria monocytogenes 26 26 20 45 30 36 45 43 32 49
Morganella morganii 26 11 18 29 30 16 30 39 40 45
Haemophilus influenzae 25 21 22 19 37 51 20 32 28 37
Fusobacterium species 15 10 8 17 14 19 18 22 26 35
Streptococcus bovis group 17 15 25 14 13 21 29 19 22 31
Bacillus 9 11 12 7 13 7 17 24 12 25
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Enterococcus, other or 
unidentified 15 24 20 25 33 34 17 21 33 22
Campylobacter species 3 5 6 3 1 4 4 13 20 20
Prevotella species 8 11 15 13 14 7 11 16 18 19
Acinetobacter 11 12 16 16 17 19 21 16 28 17
Hafnia alvei 6 8 7 7 1 8 6 4 7 14
Salmonella, other than 
Typhi or Paratyphi 8 19 6 8 7 13 9 14 3 13
Pseudomonas, other than 
aeruginosa 10 11 10 10 8 11 12 18 13 12
Propionibacterium species 4 5 9 10 13 6 7 12 18 12
Bacteroides, other than 
fragilis group 5 8 13 8 8 16 12 10 11 10
Stenotrophomonas  
maltophilia 8 3 6 7 4 8 12 7 16 8
Proteus vulgaris 9 4 4 8 8 12 14 16 15 8
Neisseria meningitidis 2 6 6 6 6 5 4 2 3 7
Capnocytophaga  
canimorsus 2 3 2 2 6 7 12 9 9 6
Haemophilus, other than 
influenzae 1 1 1 1 0 3 8 4 5 6
Mycobacterium species 1 4 0 5 1 1 1 2 5 2
Yersinia enterocolitica 1 0 1 1 0 3 0 0 0 2
Veillonella species 4 8 5 2 5 5 10 8 3 0
Yersinia pseudotuberculosis 1 0 3 1 0 1 0 0 0 0
Salmonella Paratyphi 0 0 0 0 0 0 0 0 1 0
Other bacteria 82 120 121 115 134 143 186 236 255 276
Bacteria total 5,195 5,714 6,072 6,559 6,941 7,316 8,083 9,332 9,916 10,921
Candida albicans 56 66 49 93 65 70 77 72 71 72
Other candida species 26 26 42 31 47 39 60 44 45 47
Other fungi 7 8 3 3 4 1 3 0 2 5
Fungi total 89 100 94 127 116 110 140 116 118 124
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Table 21. Group A streptococcus blood findings by emm type, 2007–2016 (no. of cases and %).
Each emm type includes all variants detected.
Year Analysed 
strains
emm1 emm28 emm4 emm89 emm33 emm12 Others
2007 205 57 (28%) 26 (13%) 7 (3%) 12 (6%) 0 (0%) 13 (6%) 90 (45%)
2008 218 51 (23%) 46 (21%) 4 (2%) 10 (5%) 0 (0%) 18 (8%) 89 (41%)
2009 191 24 (13%) 56 (29%) 8 (4%) 28 (15%) 0 (0%) 8 (4%) 67 (35%)*
2010 171 22 (13%) 38 (22%) 6 (4%) 24 (14%) 0 (0%) 13 (8%) 68 (39%)
2011 161 24 (15 %) 37 (23%) 6 (4%) 30 (19%) 0 (0%) 16 (10%) 48 (30%)
2012 207 22 (11%) 65 (31%) 13 (6%) 58 (28%) 5 (2%) 14 (7%) 30 (14%)
2013 176 18 (10%) 58 (33%) 11 (6%) 43 (24%) 13 (7%) 9 (5%) 24 (14%)
2014 205 10 (5%) 62 (30%) 17 (8%) 47 (23%) 12 (6%) 11 (5%) 46 (23%)
2015 173 19 (11%) 60 (35%) 15 (9%) 33 (19%) 2 (1%) 8 (5%) 36 (20%)*
2016 222 24 (11%) 77 (35%) 15 (7%) 41 (18%) 0 (0%) 23 (10%) 42 (19%)
*One untyped finding in 2009 and 2015.
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Table 22. Cerebrospinal fluid culture findings in patients aged 15 to 64, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Staphylococcus aureus 16 13 13 12 20 15 11 9 14 13
Streptococcus pneumoniae 14 26 20 15 12 19 13 11 17 12
Staphylococcus epidermidis 17 27 18 11 10 21 12 17 20 11
Propionibacterium species 5 4 4 7 4 5 6 13 12 10
Staphylococcus, other 
coagulase-negative 7 14 11 8 6 7 12 9 11 8
Neisseria meningitidis 16 4 8 5 7 6 1 1 3 4
Enterobacter species 2 9 3 1 2 4 2 2 1 3
Listeria monocytogenes 1 1 2 1 1 1 2 2 3 2
Haemophilus influenzae 0 3 1 0 2 1 2 3 0 2
Serratia species 3 0 0 0 1 0 0 0 1 2
Streptococcus, other beta-
haemolytic 0 1 2 1 2 1 0 1 0 1
Streptococcus viridans 
group 2 1 2 2 4 2 2 2 0 1
Streptococcus pyogenes 0 2 2 1 1 0 0 2 0 1
Mycobacterium species 1 2 0 0 1 2 0 0 1 1
Pseudomonas aeruginosa 3 4 5 3 1 4 1 2 1 1
Streptococcus milleri group 0 1 0 0 0 0 0 1 0 0
Streptococcus bovis group 0 0 0 1 0 0 0 0 0 0
Streptococcus agalactiae 5 2 0 2 0 1 1 1 4 0
Enterococcus, other or 
unidentified 1 1 0 0 1 0 0 0 0 0
Enterococcus faecium 1 0 1 0 2 2 1 0 0 0
Enterococcus faecalis 5 4 3 4 3 3 0 1 2 0
Clostridium, other than 
perfringens 0 0 0 0 0 0 0 1 0 0
Bacillus 4 3 0 0 0 2 0 0 1 0
Peptostreptococcus and 
Peptococcus 0 0 1 0 0 0 0 0 0 0
Stenotrophomonas  
maltophilia 1 0 0 0 1 0 0 0 0 0
Haemophilus, other than 
influenzae 1 0 0 0 2 0 0 0 1 0
Capnocytophaga  
canimorsus 0 0 1 0 0 1 0 1 0 0
Campylobacter species 0 0 0 0 0 0 1 0 0 0
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Acinetobacter 5 2 3 0 2 2 0 1 2 0
Bacteroides, other than 
fragilis group 0 0 0 0 0 0 0 1 0 0
Pseudomonas, other than 
aeruginosa 0 1 1 0 1 0 0 0 0 0
Salmonella, other than 
Typhi or Paratyphi 0 2 0 0 1 0 0 0 0 0
Proteus mirabilis 0 0 0 0 1 0 0 0 0 0
Morganella morganii 0 0 0 0 0 0 0 1 0 0
Klebsiella species 1 4 2 1 2 0 1 5 0 0
Escherichia coli 3 3 4 1 1 2 1 1 0 0
Citrobacter species 1 0 0 1 0 1 0 0 1 0
Other bacteria 3 2 4 0 1 2 1 5 2 1
Bacteria total 118 136 111 77 92 104 70 93 97 73
Other candida species 3 0 1 1 0 1 0 1 2 1
Candida albicans 1 0 0 0 0 1 0 0 1 0
Fungi total 4 0 1 1 0 2 0 1 3 1
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Table 23. Cerebrospinal fluid culture findings in patients aged 65 or over, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Listeria monocytogenes 2 2 2 6 4 4 4 4 6 8
Streptococcus pneumoniae 4 7 10 6 8 4 8 1 12 6
Staphylococcus, other 
coagulase-negative 2 4 3 3 1 3 5 6 3 6
Staphylococcus epidermidis 12 10 6 3 4 7 8 8 2 5
Propionibacterium species 0 2 2 1 1 2 2 9 5 4
Staphylococcus aureus 2 3 6 5 5 2 10 4 4 3
Escherichia coli 0 1 1 1 2 1 1 0 3 2
Streptococcus viridans 
group 1 0 3 1 0 3 1 0 0 1
Streptococcus milleri group 0 0 1 0 0 0 0 0 0 1
Streptococcus agalactiae 0 0 1 1 0 0 1 1 1 1
Enterococcus faecium 0 0 2 0 0 1 0 0 0 1
Enterococcus faecalis 3 0 1 0 0 2 0 2 0 1
Mycobacterium species 0 1 1 0 1 0 0 1 1 1
Haemophilus influenzae 2 1 1 0 1 0 0 0 0 1
Pseudomonas, other than 
aeruginosa 0 0 0 0 0 0 0 0 0 1
Serratia species 0 0 0 0 0 0 0 0 1 1
Klebsiella species 0 1 1 0 0 0 0 0 0 1
Enterobacter species 1 0 0 1 1 1 1 0 0 1
Streptococcus, other beta-
haemolytic 0 0 1 0 0 0 1 0 0 0
Bacillus 0 1 0 0 2 1 0 0 1 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 1 0 0 0 0
Neisseria meningitidis 0 1 0 2 0 1 1 0 0 0
Acinetobacter 1 0 0 0 0 0 0 0 0 0
Bacteroides fragilis group 0 0 1 0 0 0 0 0 0 0
Pseudomonas aeruginosa 0 2 0 0 0 1 2 0 0 0
Proteus mirabilis 0 1 1 0 0 0 0 0 0 0
Citrobacter species 0 0 0 0 1 0 1 0 1 0
Other bacteria 0 0 0 1 0 0 1 2 2 0
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2007 2008 2009 2010 2011 2012 2013 2014 2014 2015
Bacteria total 30 37 45 32 31 34 47 38 42 45
Candida albicans 0 1 0 0 0 1 0 0 0 0
Other candida species 0 0 1 0 1 0 0 1 0 0
Fungi total 0 1 1 0 1 1 0 1 0 0
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Table 24. Blood culture findings in all age groups, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Escherichia coli 2,650 2,812 2,986 3,224 3,472 3,463 3,877 4,366 4,531 4,967
Staphylococcus aureus 1,179 1,260 1,288 1,375 1,484 1,492 1,591 1,925 2,051 2,209
Klebsiella species 510 579 664 686 651 769 793 901 945 1064
Streptococcus pneumoniae 778 918 851 831 771 749 718 700 808 813
Streptococcus, other beta-
haemolytic 314 321 360 423 440 443 514 617 626 737
Staphylococcus epidermidis 665 686 679 699 644 549 642 680 739 701
Staphylococcus, other 
coagulase-negative 353 374 360 342 354 311 448 548 633 675
Enterococcus faecalis 339 311 343 341 387 409 401 490 457 486
Bacteroides fragilis group 218 255 233 289 313 286 303 386 421 470
Enterobacter species 185 210 216 260 256 276 282 259 327 376
Pseudomonas aeruginosa 262 268 265 318 293 332 325 316 338 350
Streptococcus viridans 
group 259 306 313 332 361 358 374 312 289 327
Streptococcus milleri group 119 128 121 129 146 145 190 256 274 307
Streptococcus agalactiae 213 240 250 290 230 242 258 290 301 299
Enterococcus faecium 217 220 273 280 306 281 309 372 275 286
Streptococcus pyogenes 207 220 192 171 168 216 181 211 178 229
Proteus mirabilis 109 113 120 132 115 154 140 179 182 217
Citrobacter species 56 90 90 109 87 121 123 135 143 169
Serratia species 56 78 65 82 92 90 115 103 132 156
Peptostreptococcus and 
Peptococcus 36 26 56 52 58 43 54 82 79 119
Clostridium, other than 
perfringens 52 55 69 71 62 79 69 105 99 111
Bacillus 37 46 38 43 50 40 65 89 77 82
Clostridium perfringens 53 44 66 57 59 67 42 70 73 75
Fusobacterium species 51 46 36 55 47 68 60 70 63 74
Haemophilus influenzae 54 44 46 40 64 80 47 57 52 66
Listeria monocytogenes 36 34 30 62 37 54 58 62 41 59
Morganella morganii 33 25 26 35 38 23 48 51 53 59
Campylobacter species 11 12 17 13 5 10 12 46 46 53
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Salmonella, other than 
Typhi or Paratyphi 65 64 30 53 41 48 50 44 30 52
Prevotella species 16 25 28 28 30 23 21 28 28 42
Streptococcus bovis group 24 16 33 21 19 27 33 24 31 37
Acinetobacter 36 28 39 34 40 35 37 32 49 29
Propionibacterium species 10 8 18 16 23 15 17 23 26 27
Enterococcus, other or 
unidentified 21 34 35 39 45 55 26 26 47 25
Stenotrophomonas  
maltophilia 18 22 22 23 13 16 27 24 36 18
Bacteroides, other than 
fragilis group 8 13 23 9 15 19 19 18 17 18
Hafnia alvei 7 11 13 9 3 10 7 6 9 18
Capnocytophaga  
canimorsus 10 11 13 13 23 20 26 24 21 17
Pseudomonas, other than 
aeruginosa 14 16 19 16 16 19 20 33 25 17
Neisseria meningitidis 29 22 23 29 26 21 16 16 17 15
Haemophilus, other than 
influenzae 4 5 1 3 4 14 14 10 14 12
Proteus vulgaris 12 6 7 10 10 15 16 20 19 10
Mycobacterium species 6 6 2 7 6 4 9 6 9 4
Yersinia enterocolitica 2 0 2 2 0 3 0 1 3 3
Salmonella Paratyphi 6 5 3 3 1 3 1 2 3 2
Salmonella Typhi 6 1 3 9 5 1 6 5 1 2
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 1 0 0
Veillonella species 8 11 11 8 17 10 17 16 8 0
Yersinia pseudotuberculosis 1 1 3 1 0 2 1 1 0 0
Other bacteria 182 231 246 236 253 277 329 411 430 462
Bacteria total 9,537 10,257 10,627 11,310 11,580 11,787 12,731 14,449 15,056 16,346
Candida albicans 113 126 105 154 140 128 145 129 121 126
Other candida species 57 69 71 68 85 72 106 89 96 81
Other fungi 11 10 6 4 7 3 6 3 3 6
Fungi total 181 205 182 226 232 203 257 221 220 213
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Table 25. Cerebrospinal fluid culture findings in all age groups, 2007–2016 (no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Streptococcus pneumoniae 27 38 36 26 25 24 27 16 30 20
Staphylococcus epidermidis 32 43 28 17 18 30 23 30 25 17
Staphylococcus, other 
coagulase-negative 9 22 16 11 7 12 18 15 15 16
Staphylococcus aureus 21 21 24 20 27 22 24 14 20 16
Propionibacterium species 5 6 6 8 6 7 8 24 19 15
Listeria monocytogenes 3 3 4 7 5 5 6 6 9 10
Neisseria meningitidis 24 9 12 11 11 12 8 4 5 5
Enterobacter species 3 9 4 2 3 6 3 2 1 5
Streptococcus agalactiae 13 5 7 13 3 5 3 9 8 4
Haemophilus influenzae 2 4 3 0 4 1 2 5 0 4
Streptococcus viridans 
group 3 1 7 3 5 5 3 2 2 3
Serratia species 3 0 0 0 1 0 0 0 2 3
Escherichia coli 4 5 6 4 4 4 2 3 5 3
Mycobacterium species 1 3 1 1 2 2 0 1 2 2
Streptococcus, other 
betahaemolytic 0 1 4 1 2 1 1 1 0 1
Streptococcus pyogenes 0 2 3 1 1 1 0 2 0 1
Streptococcus milleri group 0 1 1 0 0 0 0 1 0 1
Enterococcus faecium 1 0 3 0 2 3 1 0 0 1
Enterococcus faecalis 9 4 4 5 3 5 0 3 3 1
Pseudomonas, other than 
aeruginosa 0 1 1 0 1 0 0 0 0 1
Pseudomonas aeruginosa 3 6 5 3 1 5 3 2 1 1
Klebsiella species 1 5 4 1 2 1 1 5 0 1
Streptococcus bovis group 0 0 1 1 0 0 0 0 0 0
Enterococcus, other or 
unidentified 1 1 0 1 1 0 0 0 0 0
Clostridium, other than 
perfringens 0 0 0 0 0 0 0 1 0 0
Bacillus 4 4 0 0 2 3 0 1 2 0
Peptostreptococcus and 
Peptococcus 0 0 1 0 0 1 0 0 0 0
Stenotrophomonas  
maltophilia 1 0 0 0 1 0 0 0 0 0
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Haemophilus, other than 
influenzae 1 0 0 0 2 0 0 0 1 0
Capnocytophaga  
canimorsus 0 0 1 0 0 1 0 1 0 0
Campylobacter species 0 0 0 0 0 0 1 0 0 0
Acinetobacter 6 2 3 0 2 2 0 1 2 0
Bacteroides, other than 
fragilis group 1 0 0 0 0 0 0 1 0 0
Bacteroides fragilis group 0 0 1 0 0 0 0 0 0 0
Salmonella, other than 
Typhi or Paratyphi 0 2 0 0 1 0 0 0 0 0
Proteus mirabilis 0 1 1 0 1 0 0 0 0 0
Morganella morganii 0 0 0 0 0 0 0 1 0 0
Citrobacter species 2 0 0 2 1 1 1 1 2 0
Other bacteria 3 4 6 2 1 2 4 9 5 1
Bacteria total 183 203 193 140 145 161 139 161 159 132
Other candida species 3 0 2 1 1 1 0 2 2 1
Candida albicans 1 1 1 0 0 3 0 0 1 0
Fungi total 4 1 3 1 1 4 0 2 3 1
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